Protocol I8F- MC-GPGR (b)  
 
Effect of Tirzepatide on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects  
 [STUDY_ID_REMOVED] 
 
Approval Date: 14- May-2020 
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 1
Tirzepatide ( LY329 8176)Protocol I8F-MC-GPGR (b)
Effect of Tirzepatide on Oral Contraceptive 
Pharmacokinetics in Healthy  Female Subjects
Confidential Information
The information contained in this protocol is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copied by or distributed to persons not involved in the cli nical investigation of 
tirzepatide (LY3298176 ), unless such persons are bound by a confidentiality agreement 
with Eli Lilly and Company or its subsidiaries.
Note to Regulatory Authorities:   This document may contain protected personal data 
and/or commercia lly confidential information exempt from public disclosure.  Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release.  In 
the United States, this document is subject to Freedom of Information Act Exemption 4 and 
may not be reproduced or otherwise disseminated without the written approval of Eli Lilly 
and Company or its subsidiaries.
Tirzepatide (LY3298176)
Eli Lilly and Company
Indianapolis, Indiana USA 46285
Clinical Pharmacology Protocol Electronically Signed a nd Approved by Lilly on 18 Oct
2019.
Amendm ent (a) Electronically Signed and Approved by Lilly : 06 Dec 2019
Amendm ent (b) Electronically Signed and Approved by Lilly
on approval date provided below.
Approval Date: 14-May-2020 GMT
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 2
Tirzepatide ( LY329 8176)Table of Contents
Effect of Tirzepatide on Oral Contraceptive Pharmacokinetics 
in Healthy  Female Subjects
Section Page
Protocol  I8F-MC-GPGR (b) Effect of Tirzepat ide on Oral Contraceptive 
Pharmacokinet ics in Healt hy Female Subjects ..................................................................... 1
Table of Contents ........................................................................................................................ 2
1. Protocol  Synopsi s................................................................................................................ 8
2. Schedule of Activities....................................................................................................... 10
3. Introduction ...................................................................................................................... 15
3.1. Study  Rati onale............................................................................................................ 15
3.2. Background .................................................................................................................. 15
3.3. Benefit/Risk Assessment .............................................................................................. 17
4. Object ives and Endpo ints.................................................................................................. 18
5. Study  Design ..................................................................................................................... 19
5.1. Overall Design ............................................................................................................. 19
5.2. Number of Participants .................................................................................................20
5.3. End of Study  Definit ion............................................................................................... 20
5.4. Scientific Rationale for Study  Design ........................................................................... 20
5.5. Justification for Dose ................................................................................................... 21
6. Study Populat ion............................................................................................................... 22
6.1. Inclusio n Cri teria.......................................................................................................... 22
6.2. Exclusio n Cri teria........................................................................................................ 23
6.2.1. Rationale for Exclusio n of Certain Study  Candidates ........................................... 25
6.3. Lifest yle and/or Dietary Requirements ......................................................................... 25
6.3.1. Meals and Dietary  Restri ctions............................................................................. 25
6.3.2. Caffeine, Alcoho l, and Tobacco ........................................................................... 25
6.3.3. Activity................................................................................................................ 25
6.4. Screen Failures ............................................................................................................. 26
7. Treatment .......................................................................................................................... 27
7.1. Treatment Administered ............................................................................................... 27
7.1.1. Packaging and Labeling ....................................................................................... 28
7.2. Method of Treatment Assignment ................................................................................ 28
7.2.1. Selection and Timing o f Doses ............................................................................. 29
7.3. Blinding ....................................................................................................................... 29
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 3
Tirzepatide ( LY329 8176)7.4. Dose Modificat ion........................................................................................................ 29
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... 29
7.6. Treatment Compliance .................................................................................................29
7.7. Concomitant Therapy ................................................................................................... 30
7.8. Treatment After the End of the Study ........................................................................... 30
8. Discontinuati on Cri teria .................................................................................................... 31
8.1. Discontinuation fro m Study  Treatm ent......................................................................... 31
8.1.1. Discontinuati on of  Inadvertent ly Enrolled Subjects .............................................. 31
8.2. Discontinuati on from the Study .................................................................................... 31
8.3. Subjects Lost to Follow -up........................................................................................... 32
9. Study  Assessments and Procedures ................................................................................... 33
9.1. Efficacy Assessments ................................................................................................... 33
9.2. Adverse Events ............................................................................................................ 33
9.2.1. Serious Adverse Events ........................................................................................ 34
9.2.1.1. Suspected Unexpected Serious Adverse React ions.......................................... 35
9.2.2. Com plaint Handling ............................................................................................. 35
9.3. Treatment of Overdose .................................................................................................35
9.4. Safety........................................................................................................................... 35
9.4.1. Laboratory  Tests .................................................................................................. 35
9.4.1.1. Amylase and Lipase Measurements ................................................................ 35
9.4.2. Glucose Moni toring ............................................................................................. 35
9.4.2.1. Hyperglycemia and Hy poglycemia Reporting ................................................. 36
9.4.3. Vital Signs ........................................................................................................... 37
9.4.4. Electro cardiograms .............................................................................................. 37
9.4.5. Inject ion-site React ions........................................................................................ 38
9.4.6. Hypersensi tivity Reacti ons................................................................................... 39
9.4.7. Safety Moni toring ................................................................................................ 39
9.4.7.1. Hepati c Safet y................................................................................................ 40
9.5. Pharmacokinet ics......................................................................................................... 40
9.5.1. Bioanalysis ........................................................................................................... 40
9.6. Pharmacod ynamics ...................................................................................................... 41
9.6.1. Immunogenicit y Assessments .............................................................................. 41
9.7. Genet ics....................................................................................................................... 41
9.8. Biomarkers ................................................................................................................... 42
9.9. Heal th Economics ........................................................................................................ 42
10. Statistical Considerations and Data Analysis ..................................................................... 43
10.1. Sample Si ze Determinat ion.......................................................................................... 43
10.2. Popul ations for Analyses .............................................................................................. 43
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 4
Tirzepatide ( LY329 8176)10.2.1. Study  Parti cipant Disposit ion............................................................................... 43
10.2.2. Study  Parti cipant Characterist ics.......................................................................... 43
10.3. Statistical Analyses ...................................................................................................... 43
10.3.1. Safety Analyses .................................................................................................... 44
10.3.1.1. Clinical Evaluation of Safet y.......................................................................... 44
10.3.1.2. Statistical Evaluat ion of Safet y....................................................................... 44
10.3.2. Pharmacokinet ic Analyses .................................................................................... 44
10.3.2.1. Pharmacokinet ic Parameter Estimat ion........................................................... 44
10.3.2.2. Pharmacokinet ic Statistical Inference ............................................................. 44
10.3.3. Pharmacodynamic Analyses ................................................................................. 44
10.3.4. Pharmacokinet ic/Pharmacodynamic Analyses ...................................................... 45
10.3.5. Evaluat ion of Immunogenicit y............................................................................. 45
10.3.6. Data Review During the Study ............................................................................. 45
10.3.7. Interim Analyses .................................................................................................. 45
11. References ........................................................................................................................ 46
12. Appendices ....................................................................................................................... 47
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 5
Tirzepatide ( LY329 8176)List of Tables
Table Page
Table GPGR.1. Object ives and Endpo ints....................................................................... 18
Table GPGR.2. Treatments Administered ........................................................................ 28
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 6
Tirzepatide ( LY329 8176)List of Figures
Figure Page
Figure GPGR.1. Illustrati on of  stud y design for Protocol I8F -MC-GPGR. ........................ 20
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 7
Tirzepatide ( LY329 8176)List of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions................................................................ 48
Appendix 2. Clinical Laboratory  Tests ........................................................................ 51
Appendix 3. Study  Governance, Regulatory  and Ethi cal Considerati ons..................... 52
Appendix 4. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y............ 55
Appendix 5. Blood Sam pling Summary ...................................................................... 56
Appendix 6. Classificat ion of Contraceptive Methods ................................................. 57
Appendix 7. Pancreat ic Monitoring ............................................................................ 58
Appendix 8. Protocol  Amendment I8F -MC-GPGR (b) Summary 
Effect of Tirzepat ide on Oral Contraceptive Pharmacokinet ics in 
Healthy Female Subjects ........................................................................ 61
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 8
Tirzepatide ( LY329 8176)1.Protocol Synopsis
Title of Study:
Effect of Tirzepatide on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects
Rationale: 
Study I8F -MC -GPGR will assess the effect of a 5 mg subc utaneous (SC) dose of tirzepatide administered using a 
pre-filled syringe on the pharmacokinetics (PK) of an oral contraceptive (OC) in healthy female subjects.   This study 
will evaluate the potential effect of tirzepatide mediated delay in gastric emptyin g (GE)on the PK of an OC, as 
premenopausal women with diabetes could take oral contraceptives concomitantly with tirzepatide.
Objectives/Endpoints:
Objectives Endpoints
Primary
To evaluate the effect of a single SC dose of tirzepatide 
on the pharmacokinetics (PK) of a combination OCin 
healthy  female subjects.AUC(0 -tau), AUC(0 -tlast), C max
Secondary
To evaluate the safety and tolerability of a single 
subcutaneous dose of tirze patide when coadministered 
with an OC in healthy female subjects.   Incidence of adverse events (AEs)
Summary of Study Design :
This is a single -center, open -label, 2 -period, fixed sequence study with a lead-in period , in healthy female subjects.  
Subjects may already have been on OC medication prior to screening or be OC naïve.   Each subject will participate 
in 2 treatment periods and a lead -in period .
Potential subjects will be screened to assess their eligibility to enter the study within 28 days prior to Day 1 of the 
lead-in period .  On Day -1 of the lead- in period and of Periods 1 and 2 , subjects will receive a single 28 -day packet 
of the study OC (21 days of active treatment and 7 days of non -active treatment ) and will be instructed to 
self-adm inister a once -daily  (QD) dose of OC tablet at approximately the same time each day.
In Period 1, subjects will be admitted to the clinical research unit (CRU )on Day  20.  Subjects will undergo blood 
sampling for assessment of OC PK on Day 21 until 48 hour s postdose.  Subjects may be permitted to leave the CRU 
once the 48 hour OC PK blood assessment has been performed on Day 23.
In Period 2, subjects will be admitted to the CRU on Day 19.  Subjects will also receive a single SC 5 mg tirzepatide 
dose on Day 20, approximately 15 minutes after they have taken the OC .  Subjects will undergo blood sampling for 
the assessment of tirzepatide PK on Day 20 until 96 hours post dose on Day 2 4, and for the assessment of OC PK on 
Day 21 until 48 hours post OC dose on Day 23.  Subject s may be permitted to leave the CRU once the 96hour
tirzepatide PK blood assessment ha
sbeen performed on Day 24.
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 9
Tirzepatide ( LY329 8176)Treatment Arms and Planned Duration for an Individual Subject :
The study  duration for individual subjects, inclusive of screening is expected to be approximately 20 weeks, divided 
as follows:
Screening:  up to 2 8days prior to Day 1of the lead -in period
Lead -in Period and Period 1 :  Day  1 to Day  28, inclu ding QD dosing with an OC(21 days of active 
treatment [Days 1 to 21] and 7 days of non -active treatment [Days 22 to 28])
Period 2:  Day 1 to Day 28, including QD dosing with an OC (21 days of active treatment [Days 1 to 21] 
and 7 days of non -active treatment [Days 22 to 28]), and single dosing with tirzepatide on Day 20
Follow -up:  Final follow -up will occur 28 ± 1 days after tirzepatide dosing
Number of Subjects :
Approximately 42 subjects will be enrolled so that a minimum of 2 8 subjects complete the study.
Statistical Analysis:
The primary PK parameters for analysis wil l be AUC(0 -tau), AUC(0 -tlast), and C max.
Pharmacokinetic parameters will be evaluated to estimate the effect of tirzepatide on the PK of the OC ( norgestimate 
[NGM], norelgestromin [ NGMN ], and ethinyl estradiol [ EE]).  
Log-transformed C maxand AUC parameters of NGM, NGMN, and EE will be evaluated.  The differences in C max 
and AUC between OC + tirzepatide (Test) and OC alone (Reference) will be back -transformed to present the ratios 
of geometric means and the corresponding 90% confidence int erval (CI) .The t maxwill be analyzed using a Wilcoxon 
signed rank test.  Estimates of the median difference based on the observed medians, 90% CIs from the Wilcoxon 
test will be calculated.
Planned PK parameters will also be summarized with descriptive st atistics.
All Investigational product (IP) and protocol procedure AEs will be listed, and if the frequency of events allows, 
safety data will be summarized using descriptive methodology.
Safety parameters that will be assessed include safety lab parameters (including amylase, lipase, and blood glucose), 
and vital signs.  The parameters will be listed, and summarized using standard descriptive statistics, where 
appropriate.
Physical examinations and 12-lead electrocardiograms ( ECGs) will be performed for saf ety monitoring purposes and 
will not be presented. 
Additional analysis will be performed if warranted upon review of the data.
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 10
Tirzepatide ( LY329 8176)2.Schedule of A ctivities
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 11
Tirzepatide ( LY329 8176)Study Schedule Protocol I8F-MC -GPGR
Screening Lead -In Period 1FU/
EDa Comments
Procedure D-28 to -2 D-1 D1-27D-1 
(D28)D1-
13D14D15-
19D20 D21 D22 -27D28
(D-1)Note that Day -1 of Period 1 corresponds to Day 28 of 
lead-in period .
Informed Consent X
Subject Admission 
to CRUX
OCDosing
D1-27 X X X X X X X XOC active treatment on Days 1 to 21; non -active 
treatment on Days 22 to 28. Tobe taken prior to 
breakfast at approximately the same time every 
morning. Alight breakfast may be taken about 1 hour 
after dosing .
Subject Discharge 
from CRUDay 23Subjects’ CRU stay may be extended at the 
investigator’s discretion for safety monitoring.
Outpatient Visit X X D21 X X X X
Inclusion/Exclusion 
CriteriaX X
Medical History X
Physical Exam
/Medical AssessmentX X X X X X X Full physical examination during first CRU check -in. 
For all other study visits , assessments performed to 
include medical review and targeted examination, as 
appropriate.
Weight X X X X
Height X
Temperature X X
Ethanol and urine 
drug screen testingX X
Safety 12 -lead ECG 
(hours)X X X X X X Single safety ECG will be collected.  ECGs must be 
recorded before collecting any blood samples.  Subjects 
must be supine for approximately 5 to 10 minutes before 
ECG collection, and remain supine but awake during 
ECG collection.
Supine Vital Signs 
(hours)X X D21 X X X X Additional time points may be added, if warranted and 
agreed upon between Lilly and the investigator.
Clinical Laboratory 
TestsX X X X See Appendix 2 for details.
Pregnancy Test X X X X See Appendix 2 for details.
Serum Progesterone D21 Local lab assessment of compliance to OC .
Urine Cotinine Test X X
AEs/Concomitant 
MedicationsX X X X X X X X X X X X
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 12
Tirzepatide ( LY329 8176)Screening Lead -In Period 1FU/
EDa Comments
Procedure D-28 to -2 D-1 D1-27D-1 
(D28)D1-
13D14D15-
19D20 D21 D22 -27D28
(D-1)Note that Day -1 of Period 1 corresponds to Day 28 of 
lead-in period .
Pharmacogenetic 
SampleX Single sample during lead -in only.
OC PK Sampling 
(hours)Predose ,
0.25, 
0.5, 1, 
1.5, 2, 
2.5, 3, 4, 
6, 8, 10, 
12, 1624(Day  
22), 48 
(Day  23)The exact time of sampling must be recorded. A 10% 
time allowance variance will be considered acceptable.
OC sampling is relative to actual time of dosing 
(0hours ) on Day 21.
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 13
Tirzepatide ( LY329 8176)Study Schedule Protocol I8F-MC -GPGR
Period 2FU/
EDa Comments
ProcedureD-1 
(D28)D1-
13D14D15-
18D19 D20 D21 D22 -27 D28Note that Day -1 ofPeriod 2 corresponds to Day 28 
of Period 1
Subject Admission to CRU X
OCDosing
X X X X X X X X XOC active treatment on Days 1 to 21; non -active 
treatment onDays 22 to 28.  To be taken prior to 
breakfast at approximately the same time every
morning.  A light breakfast may be taken about 
1hour after dosing .
Tirzepatide SC 5 mg DosingXTo be administered approximately 15 minutes after 
OC dosing.
Subject Discharge from CRUDay 2 4Subjects’ CRU stay may be extended at the 
investigator’s discretion for safety monitoring.
Outpatient Visit X X X X
Physical Exam /Medical 
AssessmentX X Predose X X A ssessments performed to include medical review 
and targeted examination, as appropriate.
Weight X X X
Height
Temperature X
Safety 12 -lead ECG (hours) X X X Single safety ECG will be collected.  ECGs must 
be recorded before collecting any blood samples.  
Subjects must be supine for approximately 5 to 10 
minutes before ECG collection, and remain supine 
but awake during ECG collection.
Supine Vital Signs (hours) X X X X Additional time points may be added, if warranted 
and agreed upon between Lilly and the 
investigator.
Clinical Laboratory Tests X X X X See Appendix 2 for details.
Pregnancy Test X X X
AEs/Concomitant Medications X X X X X X X X X X
OC PK Sampling (hours) Predose , 0.25, 
0.5,1, 1.5, 2, 
2.5, 3, 4, 6, 8, 
10, 12, 1624 (Day 
22), 48 
(Day  23)The exact time of sampling must be recorded. A 
10% time allowance variance will be considered 
acceptable. Time of PK sampling of OC and 
tirzepatide will be referenced to actual dosing time 
of OC (Day 21 –0 hours) and tirzepatide (Day 20 
–0 hours) respectively .Time of immunogenicity 
sampling on Day 20 will be matched to tirzepatide 
predose sample. Predose samples should be 
collected within 1 hour prior to actual dosing.
In the event of immediate or non -immediate drug 
hypersensitivity reactions, unscheduled samples 
will be collected as detailed in Section 9.4.6 .Tirzepatide PK Sampling (hours) Predose,  
8, 1224 48 (Day 
22), 72
(Day  23), 
96 (Day 
24)X X
Immunogenicity Samples (hours) Predose X
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 14
Tirzepatide ( LY329 8176)Abbreviations:  AE = adverse event; CRU = clinical research unit; D or d = day; ECG = 12-lead electrocardiogram; ED = early discontinuation; OC = oral contraceptive; PK =pharmacokinetic(s). Note 
that OC PK sampling times are given relative to Day 21 dosi ng (Time 0 hour).   If multiple procedures take place at the same time point, the following order of the procedures should be used:  ECGs, 
vital signs, clinical laboratory sample, PK sample (record of actual PK sampling time is the priority), immunogenicity and pharmacogenetic sample.
aFinal follow -up will occur on Day 49 ± 1 day(i.e.,28 days ± 1 day after tirzepatide dosing )
. Early discontinuation visit should take place within 14 days upon confir mation of early discontinuation. 
Tirzepatide PK and immu nogenicity samples need not be drawn if the subject discontinues prior to receiving a dose of tirzepatide.
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 15
Tirzepatide ( LY329 8176)3.Introduction
3.1. Study Rationale
Study  I8F-MC-GPGR will assess the effect of a 5 mg subcutaneous (S C) dose of tirzepat ide 
administered using a pre -filled syringe on the pharmacokinet ics (PK) of an oral contraceptive
(OC) in healt hy female subjects.
3.2. Background
Tirzepati de (LY3298176) is being developed for the treatment of ty pe 2 di abetes mellitus 
(T2DM) as an adjunct to diet and exercise.   In addition, it is being developed as a therapy for the 
indicat ions of chronic weight management and nonalcoho lic steatohepatit is (NASH).  It is 
administered once weekly by SC inject ion.
The available preclinical and clinical data indicate that co- simulati on of  glucose -dependent 
insulinotropic polypept ide (GIP) and glucagon -like peptide (GLP -1) receptors may enhance 
insulin secret ion, improve insulin sensit ivity, and reduce body  weight bey ond the effect of 
select ive GLP -1R simu lation (Frias et al. 2018; C osku n et al . 2018).
Tirzepati de, a dual  agonist of GIP and GLP -1, is a 39 -amino acid synt hetic pept ide.  Its structure 
is based on the GIP sequence and includes a C20 fatty  di-acid m oiety that prol ongs the durati on 
of action.  It has a chemical structure a nd pharmacologic profile that is dist inct from the GLP -1 
receptor agonists due to the addit ion of GIP, which is unique amo ng the m arketed incretin 
mimet ics.
In a Phase I study  (Coskun et al .  2018) that i ncluded single and mult iple ascending dose (SAD, 
MAD ) parts, ti rzepat ide has been administered as single SC doses up to 8 mg in healt hy subjects.  
In the MAD part, higher doses up to 10 mg were attained in healt hy subjects via dose escalat ion.  
Doses up to 15 mg were achieved in pat ients with T2DM via dose escalat ion.  In thi s study , 
gastrointestinal (GI) adverse events (AEs) (nausea, vomit ing, di arrhea, abdo minal distensio n) 
and decreased appetite were the most frequently reported events by  both healthy subjects and 
also by  patients wi th T2DM and were dose related.   Mo st AEs were mild in severit y, a few were 
moderate, and none were reported as severe.  During the single ascending dose study , the hi gh 
incidence of GI AEs, notably vo miting, were considered to be dose limit ing at the 8 -mg dose; 
therefore, the 5 -mg dose was considered the maximum tolerated dose.  A dose -dependent 
increase in heart rate was detected for b oth healt hy subjects and pat ients with T2DM who 
received t irzepat ide, similar to what was observed with select ive GLP -1 receptor agoni sts.
Immunogenici ty assessment in Phase I showed low treatment -emergent anti drug ant ibody  
(TE-ADA) rate in tirzepatide -treated subjects (2.6%). Highest ADA titers in TE -ADA+ subjects 
ranged fro m 1:40 to 1:160 and showed no impact on tolerabilit y or PK profile of t irzepat ide.  A 
few subjects experienced transient elevat ions in lipase and/or amylase levels, but these episodes 
were not associated with any  relevant outcom es.  Once -weekly doses of 1, 5, 10, and 15 mg have 
been further invest igated in a Phase 2 study (Fri as et al , 2018).  An addit ional dose l evel of 
12mg and alternate dose escalat ion schemes were investigated in a 12 -week Phase 2 study .  The 
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 16
Tirzepatide ( LY329 8176)Phase 1 and 2 clinical data have not shown AEs different fro m that of available GLP -receptor 
agonists currently  marketed.
The effect of tirzepatide on gastri c em ptying (GE) has been assessed in healthy subjects and in 
patients wi th T2DM using acetaminophen pharmacokinet ics (PK) as a surrogate (Study  GPGA ). 
In healthy subjects and patients with T2DM, changes in the me an concentrati on-time profiles of 
acetaminophen suggested a dose- dependent delay in GE fo llowing a single dose of tirzepat ide. 
The delay in GE resulted in a 50% decrease in Cmaxand approximately a 1-hour delay in tmax. 
The overall AUC was not affected. The delay in GE was greatest fo llowing the first dose of 
tirzepat ide (at dose level ≥1.5 m g) and appeared to show tachyphylaxis after rep
eated dosing.
Overall, the safet y and tol erabilit y, and PK/PD profiles of tirzepatide support further 
development of tirzepat ide in pat ients with T2DM.  Further details can be found in the 
Invest igator’s Brochure (IB).   
Acombinat ion OCconsist ingof norgestimate (NGM) and ethinyl estradi ol (EE) will be used in 
this study . Norgestimate and EE are rapidly absorbed fo llowing oral  administrati on.
Norgestimate is rapidly and com pletely  metabo lized by first pass (intestinal and/or hepatic) 
mechanisms to norelgestromin (NGMN) and norgestrel (NG), which are the major active 
metabo lites of NGM. Serum concentrations of NGM fo llowing single or mult iple dosing were 
generally below assay detecti on wi thin 5 hours ; whereas NGMN appears rapidly in serum wit h 
concentrations greatly  exceeding that of NGM and has a serum t 1/2ranging from 12 to 30 hours.
Peak serum concentrati ons of NG MN and EE are generally  reached by 2 hours after
administration of the combinat ion OC . Accumulatio n following m ultiple dosing of the 0.25 mg
NGM/0.035 mg EE dose is approximately 2 -fold for NGMN and EE compared with single dose
administration. The PK of NGMN is dose proportional fo llowing NGM doses of 0.18 mg to
0.25 m g. Steady -state concentration of EE is achieved by Day 7 of each dosing cycle.
Steady state concentrations of NGMN and NG are achieved by Day  21. The eliminat ion t1/2of 
EE ranged from approximately  6 to 14 hours.
The fo llowing adverse reactions have been reported in pat ients receiving OCs and are believed to 
be drug -related: nausea, vo miting, gastrointest inal symptoms (such as abdo minal cramps and 
bloat ing), breakthrough bleeding, spotti ng, change in menstrual flow, amenorrhea, temporary  
infertilit y after discont inuat ion of treatment, edema, melasma which may persist, breast changes: 
tenderness, enlargement, secretion , change in weight (increase or decrease), change in cervical 
erosi on an d secret ion, diminut ion in lactati on when given immediately  postpartum , cholestati c 
jaundice, migraine, allergic reaction, including rash, urticaria, angioedema, mental depressio n, 
reduced tol erance to carbohy drates, vaginal candidiasis, change in corneal curvature 
(steepening), intolerance to contact lenses .An increased risk of the fo llowing seri ous adverse 
reacti ons has been associated with the use of OCs: thrombophlebit is and venous thrombosis with 
or wi thout embo lism; arterial thromboembo lism, pulm onary embo lism, myocardial infarct ion, 
cerebral hemorrhage, cerebral thrombosis, hypertensio n, gallbladder disease, hepat ic adeno mas 
or benign liver tumors. There is evidence of an associat ion between the fo llowing condi tions and 
the use of OCs: deep vein thrombosis, retinal thrombosis (Orthocy clin USPI) .
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 17
Tirzepatide ( LY329 8176)3.3. Benefit/Risk Assessment
Risks of t irzepat ide have been consistent with risks associated with other GLP -1 receptor 
agonists currently  marketed.  Potenti al risks include, but are not limited to, gastrointest inal (GI) 
effects, acute pancreatit is, increases in heart rate, and hypoglycemic events (GLP -1 receptor 
agonist class effect).
No clinically  significant safet y or tol erabilit y concerns have been identified during clinical 
investigat ion of t irzepat ide up to the highest single dose level o f 8mg or mult iple weekly  doses, 
when escalated up to 15 mg.  Based on this information, the 5-mg dose to be administered in 
Study  GPGR isreasonably ant icipated to be tolerable in this group of healt hy subjects.
There i s no anticipated therapeutic benefit in these healt hy subjects.
More informat ion about the known and expected benefits, risks, serious adverse events (SAEs), 
and reasonably ant icipated AEs of tirzepat ide are to be found in the IB.
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 18
Tirzepatide ( LY329 8176)4.Objectives and Endpoints
Table GPGR .1shows the object ives and endpo ints of the study .
Table GPGR .1. Objectives and Endpoints
Objectives Endpoints
Primary
To evaluate the effect of a single SC dose of tirzepatide 
on the pharmacokinetics (PK) of a combination OC in 
healthy  female subjects.AUC(0 -tau), AUC(0 -tlast), C max
Secondary
To evaluate the safety and tolerability of a single 
subcutaneous dose of tirz epatide when coadministered 
with an OC in healthy female subjects.   Incidence of AEs
Abbreviations:  AE = adverse event; AUC (0-tau) =area under the concentration versus time curve within 1 dosing 
interval ; AUC(0 -tlast), Cmax= maximum observed drug concentration; OC = oral contracepti ve; 
PK=pharmacokinetics; SC =subcutaneous; t max= time to maximum observed drug concentration.
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 19
Tirzepatide ( LY329 8176)5.Study  Design
5.1. OverallDesign
This is a single -center, open -label, 2 -period, fixed sequence study  with a lead- in period, in 
healt hy female subjects.  Subjects may  already have been on OC medicat ion prior to screening or 
be OC naïve.  Potential subjects will be screened to assess their eligibilit y to enter the study  
within 28 days prior to Day 1 of the lead-in period.A final fo llow
-up visit will occur on 
Day 49± 1 day  (i.e.,28 day s ± 1 day after ti rzepat ide dosing ).During each treatment period, the 
PK of individual co mponents of the OC combination will be assessed on Day  21 to enable 
evaluat ionof OC PK al one. During Period 2, ti rzepati de will be administered on Day  20such 
thatpeak exposure by  Day 21 (ti rzepati de tmax ~ 24 hours postdose) can be attained when OC
PK is evaluated on Day  21 (NGM and EE are rapidly absorbed after oral administrati on).This 
will permit studying the influence of tirzepat ide on OC PK, in the presence of maximum 
tirzepat ideexposure ; i.e.,with greatest impact on GE.
Study  governance considerations are described in detail in Appendix 3 .
Figure GPGR .1illustrates the study  design.
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 20
Tirzepatide ( LY329 8176)Abbreviations:   Adm = admission to the clinical research unit; CRU = clinical research unit; Dis = discharge from 
the clinical research unit; OC = oral contra ceptive; PK =pharmacokinetic
Figure GPGR .1. Illustration of study design for Protocol I8F-MC-GPGR .
5.2. Number of Participants
Approximately  42 subjects willbe enro lled sothat a minimum of 28 subjects complete the study .  
For purposes of this study , a subject completes the study  when all  scheduled procedures shown 
in the Schedule of Act ivities have been finished.
5.3. End of Study Definition
End of the study is the date of the last visit or last scheduled procedure shown in the Schedule o f 
Activities(Secti on 2) for the last subject.
5.4. Scientific Rationale for Study Design
A study  to eval uate the potential effect of tirzepat ide mediated delay in GE on the PK of an OC 
iswarranted, as prem enopausal  wom en wi th diabetes coul d take oral  contraceptives 
concomitant lywith tirzepat ide. Tirzepat ideis not expected to interact with the metabo lism of 
either NGM or EE. However , due to the GE del ay effect of ti rzepat ide,the PK (and thus the 
effect iveness) of an orally administered OC may  be affected.
The l ead-in peri od is intended to stabilize the PK of EEand NGM for all subjects and to 
synchronize their menstrual cycles, allo wing all subjects to be dosed on the same day .  The 

I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 21
Tirzepatide ( LY329 8176)washout period of 7 days (non -active tablets from OC packet) i s that convent ionally  used in 
norm al dosing of the OC tablet and will allow regular menstrual cycling .  
A 28 -day packet of a combinat ion OCcontaining 21 day s of tablets containing active ingredients 
(0.035 mg EEand 0.25 mg NGM ), and 7 days of non -active tablets is being used in this study, as 
it is a commo nlyprescribed OC that has been used in previous clinical studies to assess the 
impact of drugs on the PK of OCs.  The PK of EE , NGMN and NGM will be assessed in this 
study .
In addit ion to OC PK, the PK of tirzepat ide will also be assessed, to ensure that ti rzepat ide 
exposures are per the expectation fo llowing a single SC dose of 5 mg tirzepat ide.  These data 
may be used to compare with histori cal data where the impact of GEis greatest following a 
single SC dose of 5 mg tirzepatide.
Women taking OCs may show ECG changes associated with drug -induced torsade de pointes, 
such as increased corrected QT prolongat ion(Sedlak et al. 2013) .  In addition, T -wave alteration 
frequency  can also be observed.  QTc prolongat ion and T -wave morpho logical can be associ ated 
with the anti-androgenic potency  of the progestin taken, although abso lute QTc prol ongat ion is 
usually noted to be modest . Multiple ECGs pre -tirzepati de administrati on will be done so as to 
monitor such possible OC -induced changes at baseline .
5.5. Justification for Dose
Data from Phase 1 study  GPGA have shown that a 5 mg dose of tirzepatide was well tolerated by 
healt hy subjects and pat ients with T2DM and is also planned as 1 of the doses to be invest igated 
in Phase 3 studies.  Doses higher than 5 mg were achieve d via escalati on since a 5 mg dose was 
considered the maximum tolerated dose when administered as a single dose. Addit ionally, based 
on data from Study  GPGA, evaluating the effect of tirzepat ide on GE using acetaminophen as a 
probe substrate, we have obse rved that the del ay in GE i s greatest fo llowing the fi rst 5 m g dose 
of tirzepat ide and fo llowing repeated doses of tirzepatide, the effect on GE appears to show 
tachy phylaxis. Hence conducting this study  GPGR using a single 5 m g dose of ti rzepat ide will 
provi de the necessary data to evaluate the impact of t irzepat ide mediated GE delay on OC PK, if 
any. 
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 22
Tirzepatide ( LY329 8176)6.Study  Population
Eligibilit y of subjects for the study  will be largely based on the results of medical history , 
physical examinat ion, vital signs, clinical laboratory tests and 12-lead electrocardi ogram (ECG). 
The nature of any condit ions present at the time of the physical examinat ion and any preexist ing 
condi tions will  be docum ented.
Screening may occur up to 
28 days prior to enrollment.  Subjects who are not enrolled within 
28days of screening may  be subjected to an addit ional medical assessment and/or clinical 
measurements to confirm their eligibilit y.
If the invest igator decides not to administer the dose to a subject or not to enroll a subject on a 
particular day , the subject’s visit may  be rescheduled ,and any assessments or procedures 
perform ed up to that point may be repeated to confirm their eligibilit y.
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permitted.
6.1. Inclusion Criteria
Subjects are eligible for inclusio n in the study  only if they  meet all  of the f ollowing criteria:
[1] are overtly healt hy females of childbearing potential , as determined through
medical history  and physical examinat ion.
[1a] GLP -RAs do not change the PK parameters of oral contraceptives (Kapi tza 
et al.2015; Trulicit y USPI; Vi ctoza USPI; By etta USPI) .However, as a 
precauti on, the parti
cipant must agree to the fo llowing contracepti ve 
requi rements, as this study  is designed to test if tirzepa tide m ay cause the
OC tabl et to be less effect ive than usual: to either rem ain abst inent (if this is 
their pref erred and usual lifestyle) ,or to use1additional highly effect ive
method of contraception (less than 1% failure rate ; such as an interuterine 
device) and 1 addi tional effect ivemethod of contraception (such as 
diaphragm  with spermicide or cervi cal sponge), or 2 addi tional effect ive
methods of contraception f rom the screening visit unt il 2months after the
post study follow-up visi t.
Subjects reporting abst inence who beco me sexually active while on the 
study must agree to use other effect ive additional methods of contraception
(such as diaphragm wit h spermicide or cervical sponge) .
A full list of permitted highly effect ive and effect ive methods of 
contraception is presented in Appendix 6 .
[1b] must have a negative pregnancy test result at screening and at Day -1of the 
lead-in period .
[1c] must not be intending to start a family wit hin 2 months after the post study  
follow-up visit.
[2] a re between 18yearsand 45yearsof age, inclusive, at the time of scre ening .
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 23
Tirzepatide ( LY329 8176)[3] have a body  mass index of ≥ 18.5 kg/m2at screening.
[4] have clinical laboratory  test resul ts wi thin norm al reference range for the 
popul ation or invest igativesite, or resul ts wi th acceptabl e deviat ions that are 
judged to be not clinically significant by  the investigator .
[5] have venous access sufficient to allow for blood sampling per the protocol .
[
6] are reliable and willing to make themselves available for the durati on of  the 
study  and are willing to follow study  procedures .
[
7]have given written informed consent approved by Lilly and the ethical review 
board ( ERB) governing the site.
[8] have blood pressure, pulse rate, and an ECG reading that are conside red to be 
within norm al limits as determined by the invest igator.
6.2. Exclusion Criteria
Subjects will be excluded fro m study  enro llment if they meet any o f the following cri teria:
[
9] a re invest igativesite personnel  direct ly affiliated with this study  ortheir 
immediate families.  Immediate family is defined as a spouse, biological or 
legal guardian , child ,or sibling.
[
10]are Lilly  empl oyees or are em ployees of a thi rdparty  organi zation involved 
with the study .
[
11]are currently enrolled in a clinical trial involving an IPor any  other ty pe of  
medical research judged not to be scient ifically or medically co mpat ible with 
this study .  
[12]have received treatment with a drug that has not received regulatory  approval  
for any  indicati on wi thin 5 half -lives or 30 day s of screening
, whichever is 
longer.
[13] have previously completed or withdrawn fro m this study  or any  other study  
investigat ing tirzepat ide, and have previously received the IP. 
[
14]have known allergies to EE, NMG , tirzepat ide, or to related compounds or to 
any co mponents of either formulat ion.
[
15]have any abnormalit y inthe 12-lead ECG at screening that, in the opinio n of 
the invest igator, increases the risks associated with parti cipat ing in the study .
[
16]have a significant history  of  orcurrent cardiovascular (e.g., myocardial 
infarction, congest ive heart failure, cerebrovascular accident, venous 
thromboembo lism, etc.), respiratory , hepat ic, renal, GI, endocrine , 
hematol ogical (including history  of thrombocy topenia), or neurol ogical  
disorders capable o f significant ly altering the absorpti on, m etabolism , or 
eliminat ion of drugs ,or of  consti tuting a ri sk when taking the study  
medicat ion
,or interfering wit h the interpretation of data .
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 24
Tirzepatide ( LY329 8176)[17] have a history  or presence of pancreat itis (histor y of chronic pancreat itis or 
idiopathic acute pancreat itis) or gastrointestinal disorder, for example relevant 
esophageal reflux or gall bladder disease, or any  gastrointestinal  disease 
which impacts GE (e.g. ,gastric bypass surgery, pyloric stenosis, with the 
exception of appendectomy ) or coul d be aggravated by  GLP -1 analogs. 
Subjects who had an unco mplicated appendectomy, and subjects who had 
cholecysto lithiasis (removal of gall stones) and/or cho lecystectomy (remo val 
of gall bladder) in the past, with n o further sequelae, may be included in the 
study  at the di screti on of  the screening physician.
[18] r egularly use known drugs of abuse and/or show posit ive findings on drug 
screening .
[
19]have evidence of human immunodeficiency  virus (HIV) infect ion and/o r are 
positive for HIV antibodies .
[
20]have evidence of hepatit is C and/or are posit ive for hepat itis C ant ibodies.
[
21]have evidence of hepatit is B and/or are posit ive for hepat itis B surface ant igen
and/or test posit ive for hepat itis B core antibody in the absence of hepat itis B 
surface ant igen.
[
22]are unable or unwilling to refrain fro m nicotine during the study .  Any use 
within the 6 months pri or to Day -1 of the lead-in period, and/or a posit ive
cotinine test at screening or Day -
1 of the l ead-in peri od is exclusio nary.
[23] have used or plan to use over -the -coun ter or prescript ion medication, and/or 
herbal supplements (with the except ion of vitamin/mineral supplements, 
and/or thy roid repl acement therapy ) within 14 days pri or to dosing and for the 
durati on of  the study , including any  medicat ions that reduce GI motilit y, 
including, but not limited to, anti cholinergics, ant ispasm odics, 
5-hydroxy tryptamine - 3 receptor antagonists, dopamine antagonists , and 
opiates.
[24] have had a blood donation of 450 mL or more in the last 3 months, or have 
had any  blood donati on wi thin the l ast m onth pri or to screening. 
[
25]have an average weekly  alcohol  intake that exceeds 14 units per week, OR are 
unwilling to s top alcoho l consumption from 24 hours prior to each CRU visit,
while they  are resident in the CRU ,and fro m 24 hour sprior to planned 
tirzepat ide dosing until discharge fro m the study  or com pletion of  all study  
procedures (1unit of alcohol = 12 oz or 360 mL of beer; 5 oz or 150 mL of 
wine; 1.5 oz or 45 m L of dist illed spirits).
[
26]are wom en wi th a posi tive pregnancy test or women who are lactating.
[
27]have taken injectable contraceptives or have used hormonal implants within 
12 m onths of enrollment to this study  or topi cal controll ed delivery  
contraceptives (transdermal patch) or hormonal int rauteri ne devices 
(e.g.,Mirena®device) within 3 months pri or to enrollment of this study .
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 25
Tirzepatide ( LY329 8176)[28] have a contraindication to taking hormonal contraceptives, or have a history  of 
clinically significant intolerance to hormone therapy that would limit study  
participat ion or interfere with interpretation of the data, including thrombosis 
and a history  of thromboembolic disease, recurrent jaundice, acute or chronic 
liver d isease, migraines, undiagnosed vaginal bleeding, significant 
hyperlipidemia, hepat ic adeno ma, and mammary, endo metrial, or hepati c 
carcino ma or any  other estrogen -dependent neoplasia (known or suspected).
[29] have aserum  triglyceri de (TG) ≥3.4mmo l/L (300mg/dL) at screening .
[
30] a re deem ed unsui table by the invest igator for any other reason .
6.2.1. Rationale for Exclusion of Certain Study Candidates
Criteria [9] and [10] prevent conflict of interest in study  participants.  Cri teria [11] through [3 0] 
exclude me dical condi tions, medicat ion intolerance, concomitant medicat ion use that may 
confound the assessment of study  endpoints , and subjects not willing to adhere to the lifest yle 
requi rements of the study .
6.3. Lifestyle and/or Dietary Requirements
Throughout the study , subjects may undergo medical assessment sand review of compliance with 
requirements before continuing in the study .
6.3.1. Meals and Dietary Restrictions
A light breakfast might be taken about 1 hour after OC dosing.
Subjects will be require d to f ast overnight for at least 9 hours before being given a SC dose of 
tirzepat ideon Day  20 of  Period 2, and when clinical laboratory  test sam ples are taken (see 
Schedule of Act ivities[Secti on 2]).  On Day  20 of  Period 2, t irzepat ide will be administered
approximately  15minutes after OC dosing, and a light breakfast may be provided about 1 hour 
after OC dosing.
Subjects may not consume any food other than that provided by  the CRU during all inpatient 
stays.  Water m ay be consumed freely.
6.3.2. Caffeine, Alcohol, and Tobacco
No al coho l will be allowed from 24 hours prior to each CRU visit, while subjects are resident in 
the CRU, andfrom 24 hours prior to planned tirzepatide dosing unt il discharge fro m the study  or 
completion of all study  procedures.  No ni cotine use wi ll be permitted during the 6 months prior 
to Day -1 of the lead-in period or during the study .
Subjects will be allowed to maintain thei r regul ar caffeine consumpt ion throughout the study  
period (except during specific fast ing time periods).
6.3.3. Activity
No strenuous phy sical act ivity will be allowed for 48 hours prior to dosing unt il discharge from 
the study  or com pletion of  all study  procedu res.
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 26
Tirzepatide ( LY329 8176)6.4. Screen Failures
Screening tests such as clinical laboratory  tests , additional medical assessments and vital 
signs/ECGs may  be repeated at the di scret ion of the invest igator .  As this is a healt hy subject 
only study , individuals who do not meet the criteria for participat ion in this study  (screen failure) 
may not be re -screened.
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 27
Tirzepatide ( LY329 8176)7.Treatment
7.1. Treatment Administ ered
Each subject will receive 1 dose of tirzepat ide on Day  20of Period 2, administered via pre-filled 
syringe ( PFS), com prised of  1 SC injection of 5mg tirzepat ide into the abdo men.  In addit ion, 
each subject will receive one 28- day packet of the study OC(containing 21 days of activetablets
[0.035 mg EE and 0.25 mg NGM ]and 7 days of non -active tablets) on Day -1 of the l ead-in 
period and of Periods 1 and 2.  Subjects will be instructe d to take 1 tablet (beginning on Day  1) 
at approximately the same time each day .
While resident at the CRU, OCtablets will be administered orally wit h approximately 240 mL of 
room  temperature water in the mornin g in a si tting posit ion.  Subjects will not be allowed to lie 
supine for 2 hours after dosing while resident at the CRU, unless clinically indicated or for study 
procedures.  The administration of OCshoul d be followed by a light brea kfast about 1hour after
dosing.   On Day  20of Period 2, tirzepat ide will be administered approximately 15 minutes after 
OC dosing .  A light breakfast may be provided about 1 hour after OC dosing.
Subjects will be asked to take the OC tablets with a full glass of water in the s itting or standing 
position when self -administering at home.  If a subject forgets to take an OC tablet, it should be 
taken as soon as the subject remembers, with the next one taken at the normal t ime, and wit h all 
timings recorded in the dosing diary  (or equivalent).  In addit ion, if an OC tablet is not taken 
within 12 hours of the stated time, the subject must contact the CRU staff.  No medicat ion shoul d 
be discarded, even if, for whatever reason, the medicat ion was not taken.  All empt y containers 
and/or blister cards will be returned to the CRU at the end of the lead -in period and each 
treatm ent peri od so that a full drug reconciliation can be performed.  After receipt by  the sponsor 
of the final data list ings, the empt y containers will be discarded.
Thepharmacy will record all OC dispensed to subjects on a drug accountabilit y log.  All unused 
medicat ions will be returned to the pharmacy and destroy ed only  upon receiving the sponsor's 
written permissio n.  
The actual  time of all dose administrations will be recorded in the subject’s case report form 
(CRF) for inpat ient dosing days and in the diary card (or equivalent) provided by the CRU on 
outpati ent or self -administration days.   All doses of tirzepat ide will be administered inpat ient by 
clinical site staff.
Table GPGR .2shows the treatment regimens.
Prior to inject ion, the invest igator or designee will clean the subject’s skin.  Ea ch SC inject ion 
will be administered to the lower abdominal region approximately 5 cm from the umbilicus 
(i.e.,left lower quadrant and right lower quadrant), with the PFS needle applied at an appropriate 
angle.  Detailed instructions for administration wi ll be provi ded by the sponsor.  
Only a limited number of individuals will perform SC administration for consistency reasons.
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 28
Tirzepatide ( LY329 8176)Table GPGR .2. Treatment sAdministered
Treatment Name Tirzepatide Oral Contraceptive
Dosage Formulation Prefilled syringe Tablet
Dosage strength 5 mg / 0.5 mL EE 0.035 mg / NGM 0.25 mg(active) × 21 days
0mg (n on-active ) ×7 days
Route of Administration Subcutaneous Oral
Dosing I nstructions Single injection into lower abdominal 
quadrant on D ay 20in period 2Once daily ×12 weeks
The invest igator or designee is responsible for:
explaining the correct use of the Invest igational product (IP) to the site personnel
verifying that instructions are fo llowed properly
maintaining accurate records of IPdispensing and collect ion
returning all unused medication to Lilly  or its designee at the end of the study
Note : In some cases, the site may destroy  the materi al if, during the invest igativesite select ion, 
the evaluator has verified and documented that the site has appropri ate facilit ies and written 
procedures to dispose of clinical materials .
7.1.1. Packaging and Labeling
Tirzepati de will  be supplied by  the sponsor or i ts designee in accordance with current good 
manufacturing practice.
Each syringe of tirzepa tide is designed to deliver 5 mg o f tirzepat ide.
Tirzepati de, in 5 mg single -dose, disposable manual PFS, will be supplied by  Lilly , with 
study -specif ic labels, for use in the study .
Oral contraceptive willbe sourced l ocally as tablets for oral administration and wi ll be provided 
to subjects in its commercial blister pack .  The OC tablets in this study  will have the same 
concentration of the required active ingredients:  21 day s of active tablets ( 0.035 mg EEand 
0.25 mg NGM ), and 7 day s of non-active tablets.  Each subject will receive the same lot number 
of packets (if possible).
The IPwill be di spensed by  CRU pharm acy staff in accordance wit h the instructions provided by 
the sponsor.
The IPwill be labeled according to the country’s regulatory  requi rements.
7.2. Method of Treatment Assignment
All subjects will receive the same treatment.
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 29
Tirzepatide ( LY329 8176)7.2.1. Selection and Timing of Doses
The OC doses will be administered at approximate ly the same time on each day . Tirzepat ide 
will be administered on Day  20 of  Period 2.
7.3. Blinding
This study  is open -label.
7.4. Dose Modification
Dose m odificat ion is not permitted in this study .
7.5. Preparation/Handling/Storage/Accountability
The invest igator or designee must confirm appropriate temperature condit ions have been 
maintained , as communicated by s ponsor, during transit for all IPreceived and any discrepancies 
are reported and resolved before use of the study  treatm ent.
Only participants enro lled in the study may receive IPor study materials, and only authorized 
site staff may supply or administer IP.All IPshould be stored in a nenvironmentally controlled 
and mo nitored (m anual  or autom ated) area in accordance wit h the labeled storage condit ions 
with access limited to the invest igator and authorized site staff .
The invest igator is responsible for study treatment accountabilit y, reconciliat ion, and record 
maintenance ( such as recei pt, reconciliat ion and final disposit ion records) .
7.6. Treatment Compliance
On Day -1 of the l ead-in period, subjects will receive a dosing diary (or equivalent) to record 
their com pliance wi th the OC dosing during the outpati ent phase.  The actual t ime of all dose 
administrations will be recorded in the dosing diary  (or equivalent) prov ided by the CRU on 
outpati ent or self -administration days.   If a subject forgets to take an OC tablet, it should be 
taken as soon as the subject remembers, with the next one taken at the normal t ime, and wit h all 
timings recorded in the dosing diary  (or eq uivalent).  In addit ion, if an OC tablet is not taken 
within 12 hours of the stated time, the subject must contact the CRU staff.  No medicat ion shoul d 
be discarded, even if, for whatever reason, the medicat ion was not taken.
Com pliance wi th the OC during the lead -in period will be assessed by  serum  progesterone 
testing on Day  21 of  the l ead-in period.  Subjects with progesterone levels ≥3ng/mL on Day  21 
of the l ead-in period will not continue in the study .
If the PI is concerned with compliance, the PI will discuss wi th the Lilly CP or CRP to determine 
if the subject should continue with the study  or be di scontinued for non -compliance.
The IPwill be administered at the clinical site, and documentation of treatment administration 
will occur at the site.   The actual t ime of all dose administrations will be recorded in the subject’s 
CRF for inpat ient dosing days .
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 30
Tirzepatide ( LY329 8176)7.7. Concomitant Therapy
In general, concomitant medicat ion shoul d be avo ided; however, acetaminophen (1g 
maximum /dose or 3g/24 hours) may be administe red at the di scret ion of the investigator for 
treatm ent of headaches etc.  If the need for concomitant medication (other than acetaminophen ) 
arises(for exam ple, to treat an AE) , inclusio n or continuat ion of the subject may be at the 
discreti on of  the inve stigator, preferably after consultation with a Lilly Clinical Pharmaco logist 
(CP) or CRP or designee.  Any  medicati on used during the course of the study  must be 
docum ented.
7.8. Treatment After the End of the Study
Not applicable.
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 31
Tirzepatide ( LY329 8176)8.Discontinuation Criteria
Subjects discont inuing fro m the study  and treatm entprematurely for any reason shoul d complete 
adverse event and other follow -up procedures per Section 2of this protocol .
8.1. Discontinuation from Study Treatment
Discontinuati on of  the OCfor abnorm al liver tests should be considered by the invest igator 
when a subject meets 1of the f ollowing condit ions after consultation with the Lil ly-designated 
medical mo nitor:
alanine aminotransferase ( ALT ) oraspartate amino transferase (AST) >5×upper limit o f 
norm al (ULN )
ALT or AST > 3 ×ULN sustained for more than 2 weeks or
ALT or AST >3 ×ULN and total bilirubin level (TBL) >2×ULN orINR >1.5 or
ALT or AST >3 ×ULN the appearance of fat igue, nausea, vo miting, right upper-
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
alkaline phosphatase (ALP) >3 × ULN
ALP >2.5 ×ULN and TBL >2 ×ULN
ALP >2.5 × ULN with the appearance of fat igue, nausea, vo miting, right quadrant pain or 
tenderness, fever, rash, and/or eosinophilia (>5%)
8.1.1. Discontinuation of Inadvertently Enrolled Subjects
If the sponsor or invest igator ident ifies a subject who did not m eet enrollment cri teria and was 
inadvertent ly en rolled, a di scussio n must occur between the Lilly  CP/CRP and the invest igator to 
determine if the subject may cont inue in the study .  If both agree i t is medically appropriate to 
continue, the invest igator must obtain documented approval fro m the Lilly CP/CRP to allow the 
inadvertent ly enro lled subject to continue in the study  with or wi thout continued treatment with 
IP.
8.2. Discontinuation from the Study
Subjects will be discont inued in the fo llowing ci rcum stances:
Enrollment in any other clinical study  involving an IPor enrollment in any other ty pe of 
medical research judged not to be scient ifically or medically co mpat ible with this study
Parti cipation in the study  needs to be stopped for medical, safet y, regul atory , or other 
reasons consistent with applicabl e laws, regul ations, and good clinical pract ice (GCP)
Invest igator Decisio n
othe invest igator decides that the subject shoul d be discontinued from the study
oif the subject , for any  reason, requi res treatment with another therapeutic agent 
that has been demonstrated to be effect ive for treatment of the study  indicat ion, 
discontinuat ion from the study  occurs pri or to introducti on of  the new agent
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 32
Tirzepatide ( LY329 8176)Subject Decisio n
othe subject ,or legal representative ,requests to be withdrawn from the study .
Subjects m ay bediscontinued due to c linically sig nificant AEs related to the OC (as described in 
Secti on 3.2) at the discretion o f the invest igator.
8.3. Subjects Lost to Follow -up
A subject will be considered lost to follow -up if she repeatedly  fails to return for scheduled visits 
and is unable to be con tacted by  the study  site.  Si te personnel are expected to make diligent 
attem pts to contact subjects who fail to retur n for a scheduled visit or were otherwise unable to 
be followed up by the site.
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 33
Tirzepatide ( LY329 8176)9.Study Assessments and Procedures
Secti on 2lists the Schedule of Act ivities, detailing the study  procedures and their timing 
(including tolerance limit s for timing).
Appendix 2 lists the laboratory tests that wi ll be perform ed for this study .
Appendix 5 provi des a summary of the maximum  number and vo lume of invasive samples, for
all sampling, during the study .
The specificat ions in this protocol for the timings of safet y and sample co llections are given as 
targets to be achieved wit hin reasonable limits.  Modificat ions may be made to the time po ints 
based upon emerging clinical informat ion.  The scheduled t ime points may be subject to minor 
alterati ons; however, the actual time must be record ed correctly in the CRF.  Failure or delays 
(i.e.,outsi de st ipulated time allowances) in performing procedures or obtaining samples due to 
legitimate clinical issues (e.g. ,equipment technical problems, venous access difficult y, or subject 
defaul ting or b eing late on an agreed scheduled procedure) will not be considered as protocol 
deviat ions but the CRU will st ill be required to raise a file note for data reconciliat ion purpose.
Unless otherwise stated in subsect ions below, all s amples collected for speci fied laboratory  tests 
will be destroy ed wi thin 60 days of receipt of confirmed test results.  Certain samples may be 
retained for a longer period, if necessary , to com ply with applicable laws, regulat ions, or 
laboratory  certificati on standards.
9.1. Efficacy As sessments
This sect ion is not applicable for this study.
9.2. Adverse Events
Invest igators are responsible for monitoring the safety of subjects who have entered this study  
and for al erting Lilly  or its designee to any  event that seems unusual, even if this eve nt may be 
considered an unant icipated benefit to the subject.
The invest igator is responsible for the appropriate medical care of subjects during the study.
Invest igators must document their review of each laboratory  safety  report.
The invest igator remains responsible for fo llowing, through an appropriate health care option, 
AEs that are serious or otherwise medically important, considered related to the IPor the study , 
or that caused the subject to discontinue the IPbefore complet ing the study .  The subject should 
be followed unt il the event resolves, stabilizes with appropri ate di agnosti c evaluat ion, or i s 
reasonably  explained.  The frequency  of follow-up evaluat ions of the AE is left to the discret ion 
of the invest igator.
The inv estigator will record all relevant AE and SAE informat ion in the CRF.  After the
inform ed consent form (ICF) is signed, s tudy site personnel will record ,viaCRF ,the occurrence 
and nature of each subject’s preexist ing condit ions, including clinically sign ificant si gns and 
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 34
Tirzepatide ( LY329 8176)symptoms of the disease under treatment in the study .  Addit ionally, site personnel  will record 
any change in the condit ion(s) and the occurrence and nature of any AEs.  
The invest igator will interpret and document whether or not anAE h as a reasonab lepossib ility 
of being related to study treatment , the PFS , or a study procedure, taking into accoun t the 
disease, co ncomitant treatm ent or pathologies.  
A “reasonable possibilit y”means that there is a potenti al cause and effect relat ionship between 
the IP, PFS and/or study procedure and the AE.
Planned surgeries should not be reported as AEs unless the underlying medical condit ion has 
worsened during the course of the study .
If a subject’s IP is discont inued as a result of an AE, study  site personnel  must report thi s to Lilly 
or its desi gnee via CRF .
9.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in one of the fo llowing:
death
initial or prolonged inpatient hospitalizat ion
a life- threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in de ath 
or hospitalization but m ay jeopardi zethe subject or may requi re interventi on to prevent 
one of the other outcomes listed in the definit ion above
when a condit ion related to the PFS necessitates medical or surgical intervention to 
precl ude ei ther perm anent impairment of a body  function or permanent damage to a body  
structure, the seri ous outcom e of “requi red intervent ion” will be assigned
Study  site personnel  must al ert the Lilly  CRP/CP, or i ts desi gnee, of  any SAE as soon as 
pract ically possible.
Addit ionally , study site personnel  must al ert Lilly Global Patient Safet y,or its desi gnee ,of any 
SAE wi thin 24 hours of invest igator awareness of the event via a sponsor -approved method.  If 
alerts are issued via telephone, they  are to be immedi ately fo llowed with official notification on 
study -specific SAE forms.  This 24 -hour notificat ion requirement refers to the init ial SAE 
inform ation and all fo llow-up SAE information.
Invest igators are not obligated to actively seek AEs or SAEs in subjects once they ha ve 
discontinued from and/or com pleted the study  (the subject summary CRF has been co mpleted).  
However, if the invest igator learns of any SAE, including a death, at any time after a subject has 
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 35
Tirzepatide ( LY329 8176)been discharged from the study , and she considers the event re asonably possibly related to the 
study  treatm ent or study  parti cipat ion, the invest igator m ust prom ptly notify Lilly . 
Pregnancy (maternal exposure to IP) does not meet the definit ion of an adverse event.  However, 
to fulfill regulatory  requi rements any pr egnancy shoul d be reported following the SAE process to 
collect data on the outcome for both mother and fetus.
9.2.1.1. Suspected Unexpected Serious Adverse Reactions 
Suspected unexpected serious adverse react ions (SUSARs) are serious events that are not listed 
inthe IB and that the investigator reports as related to IPor procedure.  Lilly  has procedures that 
will be fo llowed f or the recording and expedited reporting of SUSARs that are consistent with 
global regulat ions and the associated detailed guida nce’s.
9.2.2. Complaint Handling
Lilly co llects product complaints on IPsand drug delivery  systems used in clinical trials in order 
to ensure the safet y of study  partici pants, m onitor quali ty, and to facilitate process and product 
improvements.
Subjects should be instr ucted to contact the invest igator as soon as possible if she has a 
complaint or probl em wi th the IPor PFS so that the situation can be assessed.
9.3. Treatment of Overdose
For the purposes of this study , an overdose of tirzepati deis considered any dose higher than the 
dose.
Refer to the IB.
9.4. Safety
9.4.1. Laboratory Tests
For each subject , laboratory  testsdetailed in Appendix 2 shoul d be conducted accordi ng to the 
Schedule of Activities (Secti on2).
9.4.1.1. Amylase and Lipase Measur ements
Serum  amylase and lipase measurements will be collected as part of the clinical laboratory  
testing and as specified in the Schedule of Activit ies (Secti on 2).  Addit ional measurements may 
be perform ed at the invest igator’s discretion. Further diagnost ic assessments will be 
recommended as per the algorithm (refer to Appendix 7 )for the m onitoring of pancreat ic events 
whenever lipase and/or amylase is confirmed to be ≥3×ULN at any visit post dose, even if the 
subje ct is asymptom atic.
9.4.2. Glucose Monitoring
Blood gl ucose m onitor m easurements m ay be taken during the study  as deemed necessary  by the 
investigator where clinically indicated.
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 36
Tirzepatide ( LY329 8176)9.4.2.1. Hyperglycemia and Hypoglycemia Reporting
Episodes of hyperglycemia (fasting plasma g lucose >270 mg/dL [15 mmo l/L]) or hy poglycemia 
(plasma glucose ≤70mg/dL [3.9 mmo l/L]) will be reported by  the investi gator or desi gnated 
physician who will be responsible for advising the subject on what further actions to take.
Addit ional monitoring m ay be requested at the investigator’s discret ion.
If the fasting plasma glucose during Periods 1 and 2, exceeds the acceptable level defined as 
hyperglycemia on 3 or more separate days over any 2 -week peri od between screening and th e 
end of the dosing period, the subject will be evaluated further at the study  site.If fast ing plasma 
glucose continues to exceed the acceptable level, treatment with an appropriate ant idiabet ic agent 
may be init iated by  the invest igator.
Hypoglycemia ep isode s will be recorded on specific CRF pages. Hypoglycemia will be treated 
appropriately  by the investi gator and addi tional moni toring of plasma glucose levels may be 
perform ed.The following categories o f the 2017 American Diabetes Associat ion posi tion
statement on glycemic targets (ADA 2017) based on recommendations of the International 
Hypoglycaemia Study  Group (IHSG 2017) should b e applied for reporti ng in the CRF and 
evaluat ing hypoglycemic events.
Hypoglycemia will be described using the following definit ions:  
Documented Glucose Alert Level (Level 1), Plasma Glucose (PG) ≤70mg/dL 
(3.9mmol/L) :  
oSymptomatic hypoglycemia :  an event during which typical symptoms of 
hypoglycemia are acco mpanied by PG ≤70mg/dL (3.9 mmo l/L)
oAsymptomatic hypoglycemia: an event not accompanied by t ypical symptoms 
of hypoglycemia but with PG ≤70 m g/dL (3.9 mmol/L)
oUnspecified hypoglycemia :an event during which PG ≤70mg/dL (3.9 mmo l/L) 
but no informat ion relative to symptoms of hypoglycemia was recorded
Documented Cli nically Significant Hypoglycemia (Level 2) PG <54 mg/dL 
(3.0mmol/L):
oSymptomatic hypoglycemia: an event during which typical symptoms of 
hypoglycemia are acco mpanied by PG <54 mg/dL (3.0 mmo l/L)
oAsymptomatic hypoglycemia: an event not accompanied by typical symptom s 
of hypoglycemia but with PG <54 mg/dL (3.0 mmol/L)
oUnspecified hypoglycemia :an event during which PG <54 mg/dL (3.0 mmo l/L) 
but no informat ion relative to symptoms of hypoglycemia was recorded
Severe hypoglycemia (Level 3): an event requiring assistance o f another person to 
actively administer carbohy drate, gl ucagon, or oth er resuscitative act ions.  During these 
episodes, the subject has an altered mental status and cannot assist in their care, is 
semico nscious or unconscious, or expe rienced coma with or without seizures and may  
requi re parenteral  therapy .Plasma glucose measurements may not be available during 
such an event, but neurological recovery  attributable to the restoration of blood glucose 
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 37
Tirzepatide ( LY329 8176)concentration to normal is consider ed sufficient evidence that the event was induced by a 
low PG concentrati on (PG ≤70 mg/dL [3.9 mmo l/L])
oSevere hypoglycemia requiring medical attention :a severe hypoglycemic 
event when subjects requi re therapy  by healt hcare professio nals (e.g., emergency
medical technicians , emergency  room  personnel, etc .
)
Other Hypoglycemia:
Nocturnal hypoglycemia: any hypoglycemic event (documented symptomat ic, 
asymptomat ic, probable symptomat ic, or severe hypoglycemia) that occurs between 
bedtime and waking
Relative h ypoglycemia: an event during which typical symptoms of hypoglycemia, that 
do not requi re the assistance o f another person, are accompanied by  PG >70 mg/dL 
(3.9mmo l/L), but these levels may be quickly approaching the 70 mg/dL (3.9 mmo l/L) 
thresho ld
Overal l (or total) hypoglycemia: This opti onal category  combines all cases o f 
hypoglycemia. If an event of hypoglycemia falls into mult iple subcategories, the event is 
only counted once in this category
Probable symptomatic hypoglycemia: An event during which symptoms of 
hypoglycemia are not accompanied by a PG measurement but that was presumably 
caused by  a blood gl ucose concentration ≤70 mg/dL (3.9 mmo l/L).
The determinat ion of a hypoglycemic event as an episode of severe hypoglycemia as defined 
above will be made by  the invest igator based on the medical need of the subject to have required 
assistance and is not predicated on the report of a subject simply ha ving received assistance.
Hypoglyc emic events will be recorded i n the hypoglyc emia m odule of the CRF to allow for the 
collect ion of co mprehensive safet y informat ion relating to these events.  All episodes of severe 
hypoglycemia will addit ionally be reporte d as SAEs (see Section 9.2.1 for details regarding SAE 
reporting).
9.4.3. Vital Signs
For each subject , vital signs measurements should be conducted accordi ng to the Schedule of 
Activities (Secti on 2).
Blood pressure and pulse rate should be measured after at least 5minutes’ supine.
Unscheduled orthostatic vital signs shoul d be assessed, if possible, during any  AE of dizziness or 
posture -induced symptoms.  Addit ional vital signs may be m easured during each study  period if 
warranted and agreed upon between Lilly and the investigator
.
9.4.4. Electrocardiograms
For each subject, ECGs should be collected according to the Schedule of Activit ies (Secti on 2).
Any clinically  significant findings from ECGs that result in a diagnosis and that occur after the 
subject receives the first dose of the IP ,shoul d be reported to Lilly ,or its desi gnee.
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 38
Tirzepatide ( LY329 8176)For each subject, a single 12-lead digital electrocardiogram (ECG) will b e collected according to 
the Schedule of Activities.  
Electrocardi ograms m ust be recorded before collect ing any blood 
samples .  Subjects must be supine for approximately  5 to 10 minutes before ECG collection and 
remain supine but awake during ECG collecti on.  Electrocardiograms may be obtained at 
additional times,when deemed clinically necessary.   All ECGs recorded should be stored at the 
investigat ional site.
Electrocardiograms will be interpreted by  a qualified physician ( the investigator or qualified 
designee) at the site as soon after the time of ECG collect ion as possible, and ideally while the 
subject is st ill present, to determine whether the subject meets entry criteria at the rele vant 
visit(s) and for immediate subject management , should any clinically re levant findings be 
ident ified.
If a clinically significant finding is ident ified (including, but not limited to ,changes in QT/QTc 
interval  from baseline) after enrollment, the investigator will determine if the subject can 
continue in the study .  The invest igator ,or qualified designee ,is responsible for determining if 
any change in subject management is needed , and must document his/her review of the ECG 
printed at the time of co llection.  Any new clinically relevant finding should be reported as an 
adverse event .
9.4.5. Injection -site Reactions
Inject ion-site assessments for l ocal tolerabilit y will be conducted, when re ported as:
an AE fro m a subject, or
a clinical observat ion from an invest igator
Reported inject ion-site reacti ons will  be characterized wi thin the fo llowing categori es:
edem a
erythema
induration
itching
pain
All injecti on-site reacti ons reported as AEs wil l be cl osely m onitored until resol ution.  The report 
of a clinically  significant AE of inject ion-site reacti on may prom pt notificati on of  the sponsor, 
clinical photography , and referral  for derm atologic evaluat ion and consideration of a skin biopsy 
and add itional unscheduled laboratory  evaluat ions (such as ALT, AST, complete blood count 
with percent eosinophils, and addit ional immunogenicit y testing).
Invest igational site staff will be provided with separate instructions/training on how to evaluate 
inject ion-site reacti ons and thei r severi ty in a consistent m anner.  Photographs of inject ion-site 
reacti ons may be taken in a standardized manner for record keeping purposes if deemed 
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 39
Tirzepatide ( LY329 8176)necessary  by the invest igator; however, the photographs will not be used to eva luate the severit y 
of inject ion-site reacti on.
9.4.6. Hypersensitivity Reactions
All hypersensit ivity react ions will be reported by  the invest igator as either AEs or, if any serious 
criterion is met, as SAEs.
In the event of suspected drug hy persensi tivity reacti ons (immediate or non -immediate) in 
subjects who experience moderate to severe inject ion reactions as assessed by the invest igator, 
unscheduled blood samples will be collected for PK and ant idrug antibody (ADA) analyses at the 
following t imepo ints:
as close as possible to the onset of the event
at the resolut ion of the event
30 (±3) day s following the event
Addit ionally , unscheduled serum  samples for immune safet y laboratory  testing (including, but 
not limited to β try ptase , total  IgE, com plement and cy tokine panel  testing) shoul d also be 
collected at approximately 60 to 120 minutes and 4 to 6 weeks after the onset of the event in 
these subjects.
Instructi ons for the collect ion and handling of blood samples will be provided by the sponsor.  
The actual  date and time (24 -hour clock) of each sampling will be recorded.
9.4.7. Safety Monitoring
The Lilly CP or CRP /scientist will mo nitor safet y data throughout the course of the study .
Lilly will review SAEs wit hin time frames mandated by co mpany procedures.  The Lilly CP or 
CRP will periodically review the following data:
trends in safety  data
laboratory  analy tes including glucose, amylase, and lipase
serious and nonserious AEs, includi ng AEs o f interest.
Further di agnosti c assessments will be recommended whenever lipase and/or amylase are 
confirmed to be ≥3 × ULN at any  visit postdose even if the subject is asymptomatic (asper the 
algorithm for the m onitoring of  pancreat ic events in Appendix 7 ) and, if pancreat itis is suspected, 
the case will be further defined using an adjudicat ion process.
When appropriate, the Lilly CPor CRP will consult with the funct ionally  independent Gl obal 
Patient Safet y therapeutic area physician or clinical research scient ist.
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 40
Tirzepatide ( LY329 8176)9.4.7.1. Hepatic Safety
If a study  subject experiences elevated ALT ≥3×ULN, ALP ≥2×ULN , or el evated total  
bilirubin ≥2×ULN, liver tests (Appendix 4) should be repeated within 3 to5 day s including 
ALT, AST, ALP, TBL, direct bilirubin , 
gamma -glutamyl  transf erase ( GGT ),and creatinine 
kinase to confirm the abnormalit y and to determine if it is increasing or decreasing.  If the 
abnorm ality persists or worsens, clinical and laboratory  monitoring shoul d be ini tiated by  the 
investigator based on consultation with the Lilly CP or CRP .  Moni toring shoul d continue unt il 
levels norm alize and/or are return ingto approximate baseline levels. 
Addit ional safet y data should be co llected if 1or more of  the f ollowing condit ions occur: 
elevation of serum  ALT to ≥ 5 ×ULN on 2or more consecutive blood tests
elevated serum TBL to ≥ 2 ×ULN (except for cases of known Gilbert’s 
syndro me)
elevation ofserum  ALP to ≥2 ×ULN on 2or more consecutive blood tests 
subject discontinued from treatment due to a hepatic event or abnormalit y of liver 
tests
hepatic event considered to be a SAE.
9.5. Pharmacokinetic s
At the visit s and t imes specified in the Schedule of Act ivities, venous blood samples o f 
approximately  3mLwill be co llected to determine the plasma concentrations of tirzepat ide, and 
6mL will be collected to determine the plasma concentrations of EE,NGMN and NGM . 
A maximum of 3 unscheduled samples m ay be collected at addit ional time points during the 
study  if warranted and agreed upon between both the investigator and sponsor.  Instructions for 
the collect ion and handling of blood samples will be provided by the sponsor.  The actual date 
and time (24 -hour cl ock time) of each sampling will be recorded.
Failure or being late (i .e., outside stipulated time allowances) to perform procedures or obtain 
samples due to legit imate clinical issues (i .e., equipment technical problems, venous access 
difficult y, or subject default ing or turning up late on an agreed scheduled procedure ) will not be 
considered as protocol deviat ions but the CRU will have to notify the sponsor in writ ing via a 
file note.
9.5.1. Bioanalysis
Samples will  be analyzed at a l aboratory  approved by  the sponsor and stored at a facilit y 
designated by  the sponsor .
Concentrations of tirzepat idewill be assayed using a validated liquid chro matography  tandem 
mass spectrometry method.   Concentrations of EE, NGMN and NGM will be assayed using 
validated liquid chro matography  with tandem  mass spectrom etry (LC/MS) m ethods.
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 41
Tirzepatide ( LY329 8176)Bioanaly tical samples collected to m easure IPconcentrations will be retained for a maximum o f 
2 years fo llowing l ast subject visit for the study .  During thi s time, samples remaining after the 
bioanalyses may  be used for expl oratory  analyses such as metabo lism work, protein binding , or 
bioanalyt icalmethod cross -validation .
9.6. Pharmacodynamic s
Not applicable.
9.6.1. Immunogenicity Assessments 
At the visit and time specified in the Schedule of Act ivities, a venous blood samplebe collected 
to determine ant ibody  producti on against the tirzepati de.Antibodies m ay be further 
characterized for cross -reactive binding to native GIP and GLP -1 and their abilit y to neutralize 
the activit y of tirzepat ide. To interpret the results of immunogenicit y, a venous blood sample 
will be co llected at the same time point to deter mine the plasma concentrations of tirzepat ide. 
All samples for immunogenicit y shoul d be taken predose when applicable and possible.
Treatment -emergent (TE) ADAs are defined in Section 10.3.5. If the immunogenicit y sample at 
the last scheduled assessment or discont inuat ion visit is TE ADA posit ive (titer >1280) , 
additional samples may be taken unt il the signal returns to baseline (i.e. ,no longer TE ADA 
positive) or for up to 1 y ear after l ast dose.   
Samples will  be retained for a m aximum  of 15 y ears aft er the l ast subject visit, or for a shorter 
period if local  regulat ions and ERBs allow, at a facilit y selected by  the sponsor.  The durati on 
allows the sponsor to respond to future regulatory  requests rel ated to tirzepat ide.  Any  samples 
remaining after 15 years will be destroyed.
9.7. Genetics
A blood sam ple will be collected for pharmacogenetic analysis as specified in the Schedule of 
Activities, where l ocal regulati ons all ow.  
Samples willnotbeused to conduct unspecified disease or populat ion genet ic res earch ei ther 
now or in the future.  Samples will be used to investigate variable exposure or response to IPand 
to invest igate genet ic variants thought to play a role in T2DM.  Assessment of variable response 
may include evaluation o f AEs or differences in efficacy.  
All samples will be coded with the subject number.  These samples and any  data generated can 
be linked back to the subject only  by the invest igativesite personnel .  
Samples will  be retained for a m aximum  of 15 y ears after the last subject vi sit, or fo r a shorter 
period if local regulat ionsand/or ERBs impose shorter time limits , for the study  at a f acilit y 
selected by Lilly or i ts desi gnee .  This retenti on peri od enables use of new techno logies, response 
to regulatory  quest ions, and invest igation of variable response that may  not be observed unt il 
later in the devel opment of tirzepat ideor after tirzepati deis co mmercially available.  
Mole cular techno logies are expected to improve during the 15-yearstorage period and therefore 
cannot be specifically  named.  However, e xisting approaches include who le geno me or exome 
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 42
Tirzepatide ( LY329 8176)sequencing, geno me wide association studies, multiplex assays, and candidat e gene studies.  
Regardless of techno logy utilized, data generated will be used only  for the specific research 
scope described in this sect ion. 
9.8. Biomarker s
Not applicable.
9.9. Health Economics
Thissection is not applicable for this study.
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 43
Tirzepatide ( LY329 8176)10. Statistical Considerations and Data Analysis
10.1. Sample Size Determination
Approximately  42 subjects will be enrolled so that a minimum of 28 subjects complete the study .
For EE AUC and C max, the intra -subject variabilit y (coefficient of variat ion [CV]) was es timated 
to be 14.2% (derived fro m Study H9X -MC-GBCQ). Based on this assumpt ion, 28 subjects will 
provi de a preci sion of 0.08 on a l og-scale. This would result in a 90% probabilit y that the half -
width of the 90% confidence interval (CI) of the ratio of the geom etric least square means for 
AUC and C maxis no larger than 7.3%.
For NGMN AUC and C max, the intra -subject variabilit y (CV) was est imated to be 1 1.3% and 
20.0%, respectively  (derived from  
Study H9X -MC-GBCQ). Based on this assumption, 
28subjects w ill provide a precision o f 0.06and 0.11 on a log- scale for AUC and C max, 
respectively . This would result in a 90% probability  that the half -width of the 90% CI of the 
ratio of the geom etric least square m eans for AUC and C maxis no larger than 5.9% and 1 0.2%, 
respectively .
10.2. Populations for Analyses
10.2.1. Study Participant Disposition
A detailed description o f subject disposit ion will be provided at the end of the study . All 
subjects who discontinue from the study  will be identified, and the extent of their part icipation in 
the study  will be reported.  If known, a reason for their discont inuation will be given.
10.2.2. Study Participant Characteristics
The subject’s age, weight, height, body mass index ( BMI ), or other demographic characteristics 
will be reported, and may be used in the PK analyses and safet y summaries as quant itative of 
classificat ion variables.   Subject age, weight, height, and BMI will be summarized as 
appropriate.
10.3. Statistical Anal yses
Statistical analysis of this study  will be the responsibilit y of EliLilly and Company  or its 
designee .
Pharmacokinet ic analyses will be conducted on data fro m all subjects who receiv eat least one 
dose of the IPand have evaluable PK .
Safety summaries will be produced for all subjects who received at least 1 dose of OC or
tirzepat ide, whether or not they  completed all protocol requirements.
Addit ional exploratory  analyses of the data will be conducted as deemed appropriate.  Study  
resul ts may be pool ed wi th the resul ts of other studies for populat ion PKanalysis purposes t o 
avoid issues with post -hoc analyses and inco mplete di sclosures of analyses.   
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 44
Tirzepatide ( LY329 8176)10.3.1. Safety Analyses
10.3.1.1. Clinical Evaluation of Safety
All IPand protocol  procedure AEs will be listed, and if the frequency o f events allows, safet y 
data will be summarized using desc riptive methodol ogy.
The incidence of symptoms for each treatment period will be presented by severit y and by 
associ ation with IPas perceived by the invest igator.  Symptoms reported to occur prior to 
enrollment will be dist inguished from those reported as new or increased in severit y during the 
study .  Each symptom  will be classified by the most suitable term fro m themedical regulatory  
dictionary.
The number of invest igational product -related SAEs will be reported.
10.3.1.2. Statistical Evaluation of Safety
Safety param eters that will be assessed include safety  lab param eters (including amylase, lipase, 
and blood glucose) ,and vital signs .  The param eters will  be listed, and summarized using 
standard descript ive statist ics, where appropri ate.
Physical examinat ions and ECGs will be performed for safet y monitoring purposes and will not 
be presented.  Additional analysis will be performed if warranted upon review o f the data.
10.3.2. Pharmacokinetic Analyses
10.3.2.1. Pharmacokinetic Parameter Estimation
Pharmacokinet ic parameter estimat es for NGM , NGMN and EE will be calculated by standard 
nonco mpart mental methods of analysis.   Planned PK parameters will be summarized with 
descript ive statistics.
The primary  parameters for analysis estimated for NGM , NGMN and EE will be m aximum  drug 
conc entrati on (C max) and area under the concentration versus time curve (AUC).  Other 
nonco mpart mental param eters, such as half -life(t1/2), apparent clearance (CL/F) , and apparent 
volume of distribut ion (V/F) may be reported.
Plasma concentrations o f tirzepat ide will be listed and summarized.
10.3.2.2. Pharmacokinetic Statistical Inference
Pharmacokinet ic parameter swill be eval uated to estimate the effect of tirzepat ide on the PK of 
the OC(NGM, NGMN, and EE) .  Log -transformed C maxand AUC parameters of NGM, 
NGMN, and EEwill be evaluated.  The differences in C max and AUC between OC + ti rzepat ide 
(Test)and OC al one ( Reference )will be back -transform ed to present the ratios of  geom etric 
means and the corresponding 90% CI.
The t maxwill be analyzed using a Wilcoxon signe d rank test.  Estimates of th e median difference 
based on th e observed m edians, 90% CIs from the Wilcoxon test will be calculated.
10.3.3. Pharmacodynamic Analyses 
Not applicable.
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 45
Tirzepatide ( LY329 8176)10.3.4. Pharmacokinetic/Pharmacodynamic Analyses
Not applicable.
10.3.5. Evaluation of Immunogenicity
The frequency and percentage of subjects with preexist ing ADA and with TE ADA to tirzepat ide 
may be tabulated.  Treatment -emergent ADAs are defined as those with a titer 2 -fold (1 dilut ion) 
greater than the minimum required dilut ion if no AD As were detected at baseline (treatment -
induced ADA) or those with a 4 -fold (2 dilut ions) increase in t iter compared to baseline if ADAs 
were detected at baseline (treatment -boosted ADA).
The frequency of cross- reactive binding to native GIP and GLP -1 and neutralizing ant ibodies 
may also be tabulated in TE ADA+ subjects, when available.
The rel ationship between the presence of ant ibodies and the PK parameters and PD response 
including safet y and efficacy  to tirzepati de may be assessed.
10.3.6. Data Review During th e Study
This sect ion is not applicable for this study.
10.3.7. Interim Analyses
No interim analyses are planned for this study .  If an unplanned interim analysis is deemed 
necessary , the Lilly CP, CRP /investigator, or designee will consult with the appropriate med ical 
director or desi gnee to determine if it is necessary  to am end the protocol .
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 46
Tirzepatide ( LY329 8176)11. References
American Diabetes Associat ion. 6. Glycemic targets: Standards of Medical Care in Diabetes —
2018. Diabetes Care .2018;41( suppl 1):S55 –S64 .
Byetta (exenat ide) USPI , 
2018.
Coskun T, Sl oop K, Loghin C, Alsina -Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA,
Cabrera O, Roell WC, Kuchibhot la U, Moyers JS, Benson CT, Gimeno RE, D’Alessio DA,
Haupt A. LY3298176, a novel dual GIP and GLP -1 receptor agonist for the treatmen t of type 2
diabetes m ellitus: From  discovery  to clinical  proof  of concept. Mol Metab. 2018;18:3 -14.
Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z,
Robins D, Haupt A. Efficacy and safet y of LY3298176, a novel dual GI P and GLP -1 receptor
agonist, in pat ients with type 2 di abetes: a randomised, pl acebo -controlled and act ive
comparator -controlled phase 2 trial. Lancet . 2018;392(10160):2180- 2193.
International Hypoglycemia Study  Group. Gl ucose Concentrations of Less Than 3.0mmo l/L 
(54mg/dL) Should Be Reported in Clinical Trials: A Joint Posit ion Statement of the American 
Diabetes Association and the European Association for the Study  of Diabetes. Diabetes Care .
2017;40(1):155 -157.
Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A. Semagluti de, a Once -Weekly 
Hum an GLP -1 Anal og, Does Not Reduce the Bioavailabilit y of the Combined Oral 
Contraceptive, Ethinylestradio l/Levonorgestrel. J Clin Pharmacol . 2015;55(5):497 –504.  
Ortho -
Cyclen USP, Oct 2013.
Sedlak T, Shufelt C, Iribarren C, Ly on LL, Bai rey Merz N. Oral  Contraceptive Use and the 
ECG: Evi dence of an Adverse QT Effect on Corrected QT In terval . Ann Noninvasive 
Electrocardiol . 2013;18(4):389 -398.
Trulicit y (dulaglut ide) USPI , 2019.
Victoza (li raglutide) USPI , 2019 .
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 47
Tirzepatide ( LY329 8176)12. Appendices
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 48
Tirzepatide ( LY329 8176)Appendix 1. Abbreviations and Definitions
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 49
Tirzepatide ( LY329 8176)Term Definition
AE adverse event:  Any untoward medical occurrence in a subject or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal
relatio nship with this treatment.  An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally associated 
with the use of a medicinal (investigational) product, whether or not relat ed to the medicinal 
(investigational) product.
CIOMS Council forInternational Organizations ofMedical Sciences
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, d urability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all the study -related requirements, good clinical practice (GCP) requirements, 
and the applicable regulatory requirements.
confirma tion A process used to confirm that laboratory test results meet the quality requirements defined 
by the laboratory generating the data and that Lilly is confident that results are accurate.  
Confirmation will either occur immediately after initial testing or will require that samples 
be held to be retested at some defined time point, depending on the steps required to obtain 
confirmed results.
CP Clinical Pharmacologist
CRP Clinical Research Physician :  Individual responsible for the medical conduct of t he study.  
Responsibilities of the CRP may be performed by a physician, clinical research scientist, 
global safety physician or other medical officer.
CV coefficient of variation
ECG 12-lead electrocardiogram
EE ethiny l estradiol
enroll The act of assigning a subject to a treatment.  Subjects who are enrolled in the study are 
those who have been assigned to a treatment.
enter Subjects entered into a study are those who sign the informed consent form directly or 
through their legally acceptable representatives.
ERB ethical review board
GCP good clinical practice
GE gastric emptying
IB Investigator’s Brochure
ICF informed consent form
ICH International Co uncil forHarmonization
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 50
Tirzepatide ( LY329 8176)informed consent A process by which a subject voluntarily confirms her willingness to participate in a 
particular study , after having been informed of all aspects of the study that are relevant to 
the subject ’sdecision to participate.  Informed consent is documented by means of a 
written, signed and dated informed consent form.  
Investigational 
Product (IP)Apharmaceutical form of an active ingredient or placebo being tested or used as a reference 
in a clinical study , including products already on the market when used or assembled 
(formulated or packaged) in a way different from the authorized form, or marketed products 
used for an unauthorized indication, or marketed products used to gain further information 
about the authorized form.
investigator A person responsible for the condu ct of the clinical study at a study site.  If a study is 
conducted by a team of individuals at a study site, the investigator is the responsible leader 
of the team and may be called the principal investigator.
Legal 
RepresentativeAn individual or judicial or other body authorized under applicable law to consent, on 
behalf of a prospective subject, to the subject ’sparticipation in the clinical study.
NGM norgestimate
Non-
investigational 
Product ( Non-IP)A product that is not being tested or used as a reference in the clinical study , but is provided 
to subjects and used in accordance with the protocol, such as:  concomitant or rescue/escape 
medication for preventative, diagnostic, or therapeutic reasons, medication to ensure 
adequa te medical care, and/or products used to induce a physiological response.
OC oral contraceptive
open -label A study  in which there are no restrictions on knowledge of treatment allocation, therefore 
the investigator and the study participant are aware of the drug therapy received during the 
study.
PK/PD pharmacokinetic/pharmacodynamic
SAE serious adverse event
screen The act of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical study .  
SUSARs suspected unexpected serious adverse reactions
TEAE treatment -emergent adverse event :  Any untoward medical occurrence that emerges during 
a defined treatment period, having been absent pretreatment, or worsens relative to the 
pretreatment state ,anddoes not necessarily have to have a causal relationship with this 
treatment 
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 51
Tirzepatide ( LY329 8176)Appendix 2. Clinical Laboratory  Tests
Safety Laboratory Tests
HematologyaClinical Chemistry (fasting)a
Hematocrit Sodium
Hemoglobin Potassium
Erythrocy te count (RBC) Bicarbonate
Mean cell volume Chloride
Mean cell hemoglobin Calcium 
Mean cell hemoglobin concentration Glucose (fasting)
Leukocytes (WBC) Blood urea
Total protein
Absolute counts of: Albumin
Neutrophils Total bilirubinh
Lymphocy tes Alkaline phosphatase
Monocytes Aspartate aminotransferase
Eosinophils Alanine aminotransferase
Basophils Creatinine
Platelets Amylase
Lipase
Urinaly sisaTriglyceride
Specific gravity
pH Hepatitis B surface antigen c,d,e
Protein Hepatitis C antibody c,d,e
Glucose HIV c,d,e
Ketones Progesterone testing (serum)f
Bilirubin Lipid Panel (Fasting)a,d
Urobilinogen Triglycerides 
Blood LDL -C
Nitrite HDL -C
Total cholesterol
Leukocytes (WBC) Ethanol and urine drug screen testingc,g
Microscopic examination of sedimentbUrine cotininea,g
Abbreviations:  HDL = high density lipoprotein cholesterol ; HIV = human immunodeficiency virus; LDL = low 
density  lipoprotein cholesterol ; RBC = red blood cells; WBC = white blood cells.
aPerformed by local laboratory.  Results will be validated by the laboratory at the time of initial tes ting.
bTest only if dipstick result is abnormal (i .e., positive for blood, protein, or nitrites).
cPerformed by local laboratory.
dAt screening only.
eTests may be waived if they have been performed within 6 months before screening with reports available for 
review.
fDay 21 of the lead -in period only.
gScreening and Day -1 of the lead-in period only.
hIf total bilirubin is >upper limit of normal, reflect and indirect bilirubin should be measured.
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 52
Tirzepatide ( LY329 8176)Appendix 3. Study  Governance, Regulatory  and Ethical 
Considerations
Informed Consent
The invest igator is responsible for:
ensuring that the subject understands the nature of the study ,the potential risks and 
benefits of part icipating in the study , and that thei r parti cipat ion is vo luntary.
ensuring that informed consent is given by each subject or legal representative.  This 
includes obtaining the appropriate signatures and dates on the ICF prior to the 
perform ance of any protocol  procedures and prior to the administration of IP.
answering a ny quest ions the subject may  have throughout the study  and sharing in a 
timely  manner any  new inform ation that m ay be relevant to the subject ’swillingness to 
continue her participat ion in the study .
provi ding a copy  of the ICF to the parti cipant or the pa rticipant’s l egal representative and 
retaining a copy  on file .
Recruitment
Lilly or i ts desi gnee is responsible for the central recruit ment strategy  for subjects .  Individual 
investigators may have addit ional local requirements or processes.   Study -specific recruit ment 
materi al should be approved by Lilly .
Ethical Review
The invest igator must give assurance that the ERB was properly const ituted and convened as 
requi red by ICH gui delines and other applicable laws and regulations.
Docum entati on of  ERB approval  of the protocol and the ICF must be provided to Lilly  before the 
study  may begin at the investi gative si te.  Lilly or its representatives must approve the ICF 
before i t is used at the invest igative site.  All ICFs must be compliant with the ICH gu ideline on 
GCP.
The study  site’s ERB shoul d be provided wi th the fo llowing:
the current IB and updates during the course of the study
ICF
relevant curri cula vi tae
Regulatory Considerations
This study  will be conducted in accordance wit hthe protocol and wi th:
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 53
Tirzepatide ( LY329 8176)1)consensus ethics principles derived fro m internat ional ethics guidelines, 
including the Declarat ion of Helsinki and Council for International 
Organizat ions of Medical Sciences (CIOMS) Internat ional Ethi cal Guidelines 
2)applicable ICH GCP Guidelines 
3)applicable laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third party  organizat ion.
Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of the 
study .  
After reading the protocol, each principal invest igator will sign the protocol signature page and 
send a copy  of the signed page to a Lilly representative.
Final Report Signature
The invest igator or designee will sign the clinical study report for this study, indicat ing 
agreem ent wi th the analyses, results, and conclusio ns of the report.
The sponsor’s responsible medical o fficer and statistician will sign/approve the final clinical 
study  report for this study , confirming that, to the best of his or her knowledge, the report 
accurately describes the conduct a nd results of the study.
Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate.
provi detraining to i nstruct the invest igators and study  coordinators.  This training will 
give instruction on the protocol, the complet ion of the CRFs, and study  procedures.
make periodic visit s to the study  site.
be available for consultation and stay  in contac t with the study  site personnel by  mail, 
telephone, and/or fax.
review and evaluate CRF data and/or use standard computer edits to detect errors in data 
collect ion.
conduct a qualit y review of the database .
In addit ion, Lilly or its representatives willperiodically check a sample of the subject data 
recorded against source documents at the study  site.  The study  may be audi ted by  Lilly and/or 
regul atory  agencies at any  time.  Invest igators will be given notice before an audit occurs.
The invest igator will keep records of all original source data.  This might include laboratory  
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 54
Tirzepatide ( LY329 8176)applicable regulatory  agencies, and applicable ERBs with direct access to the ori ginal  source 
docum ents.
Data Collection Tools/Source Data
An electronic data capture sy stem  will be used in this study .  The site must define and retain all 
source records and must maintain a record of any data where source data are directly entered into 
the data capture system.
Data Protection
Data systems used for the study  will have control s and requi rements in accordance wit h local 
data protecti on law.
The p urpose and use of subject personal information collected will be provided in a written 
docum ent to the subject by  the sponsor .
Study and Site Closure
Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly  or its desi gnee , the invest igator , or the ERB 
of the study  sitejudges it necessary for medical , safet y, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
Discontinuation of the Study
The study  will be discontinued if Lilly or its designee judges it necessary  for m edical, safet y, 
regul atory , or other reasons consistent with applicable laws, regulat ions, and GCP.
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 55
Tirzepatide ( LY329 8176)Appendix 4. Hepatic Monitoring Tests for Treatment -
Emergent A bnormality
Selected tests m ay be obtained i n the event of a treatment -emergent hepatic abnormalit y and may  
be required in fo llow-up wi th subjects in consultation with Lilly or i ts desi gnee CRP .
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrom bin Time
WBC Prothrombin Time, INR
Neutrophils
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B Core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Conjugated bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti -nuclear antibody a
AST Alkaline Phosphatase Isoenzymes a
GGT
CPK Anti -smooth muscle antibody (or anti -actin 
antibody) a
Abbreviations:  ALT = alanine aminotransferase; AST = asp artate aminotransferase; CPK = creatinine 
phosphokinase; GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normalized
ratio; RBC = red blood cells; WBC = white blood cells.
aAssay ed by Lilly -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability .
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 56
Tirzepatide ( LY329 8176)Appendix 5. Blood Sampling Summary
This table summarizes the approximate number of venipunctures and blood volumes for all 
blood sam pling (screening, safet y laboratori es,and bioanaly tical assays) during the study .
Protocol I8F-MC -GPG RSampling Summary
PurposeBlood Volume 
per Sample (mL)Estimated Number 
ofBlood SamplesTotal 
Volume (mL)
Screening tests (local laboratory) a 24 1 24
Clinical laboratory tests (local laboratory) a 10 6 60
OC Pharmacokinetics (central / referral laboratory) b
Study visits ( 2periods)6 16 × 2 periods (+ 3 
unscheduled) = 35210
Tirzepatide Pharmacokinetics (central / referral 
laborato ry)3 9 27
Immunogenicity (central or referral laboratory) 10 2 20
Pharmacogenetics (stored sample) 10 1 10
Total 351
Total for clinical purposes rounded up to nearest 10 mL 360
aAdditional samples may be drawn if needed for safety purposes.
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 57
Tirzepatide ( LY329 8176)Appendix 6. Classification of Contraceptive Methods
Highly Effective (Less Than 1% Failure Rate) Methods of Contraception:
Intrauterine device (such as ParaGard®)
Bilateral tubal ligat ion
Bilateral tubal occlusio n(such as Essure)
Hysterectomy  without bilateral  oophorectomy
Bilateral salpingectomy
Total  abstinence or in a same -sex rel ationship (if this is their preferred and usual 
lifest yle).  Note:  periodic abst inence ( for example , calendar, ovul ation, symptother mal, 
postovulat ion methods), declarat ion of abst inence just for the duration of a trial, and 
withdrawal  are not acceptabl e methods of contraception
Vasectomy  –for male partners of women in clinical trials
Effective Methods of Contraception:
Male condom wi th spermicide *
Female condo m with spermicide *
Diaphragm  with spermicide
Cervical sponge
Cervical cap wit h spermicide
* The use of male and female condoms as a double -barrier method is not considered acceptable.
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 58
Tirzepatide ( LY329 8176)Appendix 7. Pancreatic Monitoring
Glucagon -like pepti de-1 agoni sts have been associated with a possible risk of acute pancreat itis.  
In2006, the United States prescribing informat ion for exenat ide was revised to include the event 
of pancreati tis.  In 2007, the United States prescribing information for this medication was 
amended to include pancreat itis under “Precaut ions.”  Epi demi ologic studi es have indicated that 
there is an increased incidence and prevalence of pancreat itis in persons with T2DM.
To enhance understanding of the natural variability o f pancreat ic enzymes in the T2DM 
popul ation and, in order to assess for any potential effects of tirzepat ide on the exocrine 
pancreas, amylase and lipase values will be monitored in all current and future clinical trials wit h 
tirzepat ide.
Addit ional monitoring will be requested for amylase and/or lipase values ≥3 × ULN at any  visit, 
even in asymptomat ic subjects (see figure below).  Lipase and amylase values may also be 
obtained at any  time during the clinical trials for any subject suspected of having sympto ms 
suggest ive of exenat ide pancreat itis (such as severe GI signs and/or symptoms), at the 
investigator’s discret ion.
Acute pancreat itis is an AE defined as an acute inflammatory  process of the pancreas that may 
also invo lve peripancreatic tissues and/or re mote organ systems.  The diagnosis of acute 
pancreat itis requires 2 of the fo llowing 3 features:
abdo minal pain characteristic of acute pancreatit is
serum  amylase and/or lipase ≥3 × ULN
characterist ic findings of acute pancreat itis on CT scan or magnet ic resonance 
imaging
Most subjects with acute pancreatit is experience abdo minal pain that is located generally in the 
epigastri um, and radiates to the back in approximately  one-half of the cases.  The pain is often 
associ ated wi th nausea and vo miting.  However , experience wit h GLP -1 agoni sts has 
demonstrated that som e subjects asymptomat ic for classic pancreatit is may demo nstrate 
significant el evations of lipase and/or amylase.  For subjects considered by invest igators to be 
asymptomat ic for pancreat itis, but w hose value(s) for lipase and/or amylase are ≥3 × ULN, an 
algorithm is in place to fo llow these subjects safely  and to qui ckly reach (or n ot reach) a 
diagnosis of pancreat itis.
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 59
Tirzepatide ( LY329 8176)Abbreviations:  CT = computed tomography; MRI = magnetic resonance imaging ; 
ULN = upper limit of normal .

I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 60
Tirzepatide ( LY329 8176)Subjects diagnosed with pancreat itis will be discontinued fro m the study .  Invest igators will be 
responsible for fo llowing, through an appropriate healthcare option, these pancreat itis AEs unt il 
the events resolve or are explained.  Adverse events that meet the diagnostic criteria of acute 
pancreat itis will be captured as SAEs.  For all other pancreatic AEs (such as idiopathic or 
asymptomat ic pancreat ic enzyme abnormalit ies), the invest igator will be responsible for 
determining the seri ousness of the event (AE or SAE) and the relatedness of the event to study  
drug.
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 61
Tirzepatide ( LY329 8176)Appendix 8. Protocol Amendment I8F-MC-GPGR ( b) 
Summary  
Effect of Tirzepatide on Oral Contraceptive 
Pharmacokinetics in Healthy  Female Subjects
Overview
Protocol  I8F-MC-GPGR ‘Effect of Tirzepat ide on Oral Contraceptive Pharmacokinet ics in 
Healthy Female Subjects ’has been amended.  The new protocol is indicated by  Amendment ( b) 
and will be used to conduct the study  in place of any  preceding versio n of the protocol.   Thi s 
amendm ent is considered to be substantial since one of the primary  object ive endpo int 
measurements has been changed.
The overall changes and rationale for the changes made to this protocol are as fo llows:
Exclusio n criterion [29] was updated to exclude healthy  participants wi th a serum  
triglyceri de level ≥3.4 mm ol/L (300 m g/dL) at screening . This update ensures that 
participants wi th CTCAE Grade 2 hypertriglyceridemia (i.e., >300 mg/dL) will not be 
enrolled.
The primary endpo ints were changed from AUC(0 -∞), AUC (0- t last) and C maxto 
AUC(0 -tau), AUC(0-t last) and C max. AUC(0 -tau) at steady  state approximates AUC(0 -∞) 
after a single dose, and hence AUC (0-tau)isa more sui table endpoint than AUC(0 -∞)
for this study , 
where PK o f the OC is measured only at steady  state.
Sample size calculat ions were adjusted based on the change of the primary object ive 
endpo int from AUC(0 -∞)to AUC(0 -tau).  
The l ength of the overnight fast prior to Peri od 2 Day  20 and prior to when clinical 
laboratory  samples are collected was ex tended from 8 hours to 9 hours.   
Thefull physical examinat ion was m oved from  screening to prior to the first CRU 
check -in.  Thi s update reduce ssubject contacts from full physical examinat ions and 
limit sit only  to those who have passed preliminary inclu sion/exclusio n criteria. This is 
part of the site effort to reduce potential COVID -19 exposures .  
Minor edi torial changes and formatting corrections were made but are not necessarily 
docum ented in the revisio n below.
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 62
Tirzepatide ( LY329 8176)Revised Protocol Sections
Note: All deletions have been ident ified by strikethroughs .
All additions have been ident ified by the use of underscore .
1 Protocol Sy nopsis
Objectives/Endpoints:
Objectives Endpoints
Primary
To evaluate the effect of a single SC dose of tirzepatide 
on the pharmacokinetics (PK) of a combination OCin 
healthy  female subjects.AUC (0-∞) (0-tau) , AUC(0 -tlast), C max
Secondary
To evaluate the safety and tolerability of a single 
subcutaneous dose of tirzepatide when coadministered 
with an OC in healthy female subjects.   Incidence of adverse events (AEs)
Statistical Analysis:
The primary PK parameters for analysis will be AUC (0-∞) (0-tau) , AUC(0 -tlast), and C max.
Pharmacokinetic parameters will be evaluated to estimate the effect of tirzepatide on the PK of the OC ( norgestimate 
[NGM], norelgestromin [ NGMN ], and ethinyl estradiol [ EE]).  
Log-transformed C maxand AUC parameters of NGM, NGMN, and EE will be evaluated.  The differences in C max 
and AUC between OC + tirzepatide (Test) and OC alone (Reference) will be back -transformed to present the ratios 
of geometric means and the corresponding 90% confidence interval (CI) .The t maxwill be analyzed using a Wilcoxon 
signed rank test.  Estimates of the me dian difference based on the observed medians, 90% CIs from the Wilcoxon 
test will be calculated.
Planned PK parameters will also be summarized with descriptive statistics.
All Investigational product (IP) and protocol procedure AEs will be listed, and if the frequency of events allows, 
safety data will be summarized using descriptive methodology.
Safety parameters that will be assessed include safety lab parameters (including amylase, lipase, and blood glucose), 
and vital signs.  The parameters will be lis ted, and summarized using standard descriptive statistics, where 
appropriate.
Physical examinations and 12-lead electrocardiograms ( ECGs) will be performed for safety monitoring purposes and 
will not be presented. 
Additional analysis will be performed if warranted upon review of the data.
2 Schedule of A ctivities
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 63
Tirzepatide ( LY329 8176)Study Schedule Protocol I8F -MC -GPGR
Screening Lead -In Period 1FU/
EDa Comments
Procedure D-28 to -2 D-1 D1-27D-1 
(D28)D1-
13D14D15-
19D20 D21 D22 -27D28
(D-1)Note that Day -1 of Period 1 corresponds to Day 28 of 
lead-in period.
Informed Consent X
Subject Admission 
to CRUX
OCDosing
D1-27 X X X X X X X XOC active treatment on Days 1 to 21; non -active 
treatment on Days 22 to 28. Tobe taken prior to 
breakfast at approximately the same time every 
morning. Alight breakfast may be taken about 1 hour 
after dosing .
Subject Discharge 
from CRUDay 23Subjects’ CRU stay may be extended at the 
investigator’s discretion for safety monitoring.
Outpatient Visit X X D21 X X X X
Inclusion/Exclusion 
CriteriaX X
Medical History X
Physical Exam
/Medical AssessmentX X X X X X X Full physical examination at screening during first CRU 
check -in. Thereafter For all other study visits , 
assessments performed to include medical review and 
targeted examination, as appropriate.
Weight X X X X
Height X
Temperature X X
Ethanol and urine 
drug screen testingX X
Safety 12 -lead ECG 
(hours)X X X X X X Single safety ECG will be collected.  ECGs must be 
recorded before collecting any blood samples.  Subjects 
must be supine for approximately 5 to 10 minutes before 
ECG collection, and remain supine but awake during 
ECG collection.
Supine Vital Signs 
(hours)X X D21 X X X X Additional time points may be added, if warranted and 
agreed upon between Lilly and the investigator.
Clinical Laboratory 
TestsX X X X See Appendix 2 for details.
Pregnancy Test X X X X See Appendix 2 for details.
Serum Progesterone D21 Local lab assessment of compliance to OC.
Urine Cotinine Test X X
AEs/Concomitant 
MedicationsX X X X X X X X X X X X
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 64
Tirzepatide ( LY329 8176)Screening Lead -In Period 1FU/
EDa Comments
Procedure D-28 to -2 D-1 D1-27D-1 
(D28)D1-
13D14D15-
19D20 D21 D22 -27D28
(D-1)Note that Day -1 of Period 1 corresponds to Day 28 of 
lead-in period.
Pharmacogenetic 
SampleX Single sample during lead -in only.
OC PK Sampling 
(hours)Predose, 
0.25, 
0.5, 1, 
1.5, 2, 
2.5, 3, 4, 
6, 8, 10, 
12, 1624 (Day 
22), 48 
(Day  23)The exact time of sampling must be recorded. A 10% 
time allowance variance will be considered acceptable. 
OC sampling is relative to actual time of dosing 
(0hours) on Day 21.
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 65
Tirzepatide ( LY329 8176)Study Schedule Protocol I8F -MC -GPGR
Period 2FU/
EDa Comments
ProcedureD-1 
(D28)D1-
13D14D15-
18D19 D20 D21 D22 -27 D28Note that Day -1 of Period 2 corresponds to Day 28 
of Period 1
Subject Admission to CRU X
OCDosing
X X X X X X X X XOC active treatment on Days 1 to 21; non -active 
treatment on Days 22 to 28.  To be taken prior to 
breakfast at approximately the same time every 
morning.  A light breakfast may be taken about 
1hour after dosing .
Tirzepatide SC 5 mg DosingXTo be administered approximately 15 minutes after 
OC dosing.
Subject Discharge from CRUDay 24Subjects’ CRU stay may be extended at the 
investigator’s discretion for safety monitoring.
Outpatient Visit X X X X
Physical Exam /Medical 
AssessmentX X Predose X X Full physical examination at screening. Thereafter, 
assessments performed to include medical review 
and targeted examination, as appropriate . 
Assessments performed to include medical review 
and targeted examination, as appropriate.
Weight X X X
Height
Temperature X
Safety 12 -lead ECG (hours) X X X Single safety ECG will be collected.  ECGs must 
be recorded before collecting any blood samples.  
Subjects must be supine for approximately 5 to 10 
minutes before ECG collection, and remain supine 
but awake during ECG collection.
Supine Vital Signs (hours) X X X X Additional time points may be added, if warranted 
and agreed upon between Lilly and the 
investigator.
Clinical Laboratory Tests X X X X See Appendix 2 for details.
Pregnancy Test X X X
AEs/Concomitant Medications X X X X X X X X X X
OC PK Sampling (hours) Predose, 0.25, 
0.5, 1, 1.5, 2, 
2.5, 3, 4, 6, 8, 
10, 12, 1624 (Day 
22), 48 
(Day  23)The exact time of sampling must be recorded. A 
10% time allowance variance will be considered 
acceptable. Time of PK sampling of OC and 
tirzepatide will be referenced to actual dosing time 
of OC (Day 21 –0 hours) and tirzepatide (Day 20 
–0 hours) respectively. Time of immunogenicity 
sampling on Day 20 will be matched to tirzepatide 
predose sample. Predose samples sho uld be 
collected within 1 hour prior to actual dosing.Tirzepatide PK Sampling (hours) Predose,  
8, 1224 48 (Day 
22), 72 
(Day  23), 
96 (Day 
24)X X
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 66
Tirzepatide ( LY329 8176)Period 2FU/
EDa Comments
ProcedureD-1 
(D28)D1-
13D14D15-
18D19 D20 D21 D22 -27 D28Note that Day -1 of Period 2 corresponds to Day 28 
of Period 1
Immunogenicity Samples (hours) Predose X In the event of immediate or non -immediate drug 
hypersensitivity reactions, unscheduled samples 
will be collected as detailed in Section 9.4.6 .
Abbreviations:  AE = adverse event; CRU = clinical research unit; D or d = day; ECG = 12-lead electrocardiogram; ED = early discontinuation; OC = oral contraceptive; PK =pharmacokinetic(s). Note 
that OC PK sampling times are given relative to Day 21 dosing (Time 0 hour).   If multiple procedures take place at the same time point, the following ord er of the procedures should be used:  ECGs, 
vital signs, clinical laboratory sample, PK sample (record of actual PK sampling time is the priority), immunogenicity and ph armacogenetic sample.
aFinal follow -up will occur on Day 49 ± 1 day (i.e., 28 days ± 1 day after tirzepatide dosing).  Early discontinuation visit should take place w ithin 14 days upon confir mation of early discontinuation.  
Tirzepatide PK and immunogenicity samples need not be drawn if the subject discontinues prior to receiving a dose of tirzepatide.
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 67
Tirzepatide ( LY329 8176)4 Objectives and Endpoints
Table GPGR.1 Objectives and Endpoints
Objectives Endpoints
Primary
To evaluate the effect of a single SC dose of tirzepatide 
on the pharmacokinetics (PK) of a combination OC in 
healthy  female subjects.AUC (0-∞) (0-tau) , AUC(0 -tlast), C max
Secondary
To evaluate the safety and tolerability of a single 
subcutaneous dose of tirzepatide when coadministered 
with an OC in healthy female subjects.   Incidence of AEs
Abbreviations:  AE = adverse eve nt; AUC (0-∞) (0-tau) =area under the concentration versus time curve from zero 
to infinity within 1 dosing interval ; AUC(0 -tlast), Cmax= maximum observed drug concentration; OC = oral 
contracepti ve; PK =pharmacokinetics; SC =subcutaneous; t max= time to maximum observed drug concentration.
6.2Exclusion Criteria
[29]have a serum  triglyceri de (TG) ≥53.4mmo l/L (442.5 300mg/dL) at 
screening. 
6.3.1. Meals and Dietary  Restrictions
A light breakfast might be taken about 1 hour after OC dosing.
Subjects will be required to fast overnight for at least 8 9hours before being given a SC dose of 
tirzepat ide on Day 20 of Period 2, and when clinical laboratory test samples are taken (see 
Schedule of Act ivities [Section 2]).  On Day  20 of  Period 2, ti rzepatide will be administered 
approximately  15 minutes after OC dosing, and a light breakfast may be provided about 1 hour 
after OC dosing.
10.1 Sample Size Determination
Approximately  42 subjects will be enrolled so that a minimum of 28 subjects complete t he study.
For EE AUC and C max, the intra -subject variabilit y (coefficient of variat ion [CV]) was estimated 
to be 18.2% and 14.2% , respectively (derived fro m Sstudy H9X -MC-GBCQ).  Based on this 
assumpt ion, 28 subjects will provide a precisio n of 0.10 and 0.08 on a log- scale for AUC and 
Cmax, respectively .  This woul d resul t in a 90% probabilit y that the half -width of the 90% 
confidence interval (CI) of the ratio of the geometric least square means for AUC and C maxis no 
larger than 9.3% and 7.3% , respectivel y.
For NGMN AUC and C max, the intra -subject variabilit y (CV) was est imated to be 16.3% 11.3% 
and 20.0%, respectively (derived fro m Sstudy H9X -MC-GBCQ).  Based on this assumpt ion, 
28subjects will provide a precision o f 0.090.06 and 0.11 on a log- scale for AUC and C max, 
respectively .  This woul d resul t in a 90% probability  that the half -width of the 90% CI of the 
I8F-MC-GPGR Clinical Pharmacology Protocol (b) Page 68
Tirzepatide ( LY329 8176)ratio of the geom etric least square m eans for AUC and C maxis no larger than 8.3% 5.9% and 
10.2%, respectively .  
Leo Document ID = 885eeb45-8122-4e6f-824a-605feb7b056e
Approver:
Approval Date & Time: 14-May-2020 02:27:54 GMT
Signature meaning: Approved
PPD